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1 Introduction  
1.1 Pattern recognition by the innate immune system  
The innate immune system is the first and immediate defense against diverse pathogens 
including bacteria, viruses, fungi and parasites. For a long time, its role was underestimated 
as an unspecific reaction, until 1989 Charles Janeway proposed pattern recognition to form 
a main characteristic of innate immunity. In his model pattern recognition receptors (PRRs) 
can distinguish between “self” and “non-self” by detecting conserved microbial components 
– the pathogen associated molecular patterns (PAMPs) - and can subsequently initiate an 
adaptive immune response (1,2). In the following years this model could be verified by 
identification and characterization of several PRRs.  
Based on their structural features, the PRRs can be classified into five main families: Toll-like 
receptors (TLRs), NOD-like receptors (NLRs), C-type-lectine receptors (CLRs), AIM2-like-
receptors (ALRs) and RIG-I-like receptors (RLRs).  
The longest known and best characterized group are the TLRs. In most vertebrates 10 to 15 
members are known. Nine of which (TLR1 to TLR9) are conserved in human and mice (3). 
Regarding their localization the TLRs can be subdivided into two groups.  TLR1, TLR2, TLR4, 
TLR5 and TLR6 are localized in the cell membrane and detect membrane components of 
bacteria and fungi, such as lipids, proteins and lipoproteins in the extracellular space. TLR3, 
TLR7, TLR8 and TLR9 are predominantly expressed in the endosomal membrane and 
recognize nucleic acids derived from viruses or bacteria (3,4).  
The NLRs include 22 known members in humans. But only a few of them have been 
functionally characterized so far. All of them are expressed in the cytoplasm where they 
detect a broad spectrum of PAMPs. This includes peptidoglycans of bacteria (NOD1 and 
NOD2), viral and bacterial nucleic acids, as well as metabolic changes induced by different 
toxins of bacteria and fungi (NLRP3) (5). 
The CLRs are a group of PRRs that are expressed at the cell surface and recognize different 
carbohydrates, such as mannose, fucose and glucan allowing the detection of a variety of 
bacteria, fungi, viruses and parasites (6).   
Four ALRs are known to exist in human (AIM2, IFI16, PYHIN1 and MNDA). They all recognize 
DNA derived from viruses or bacteria and are expressed in the cytoplasm or nucleus (IFI16) 
(7,8). The latest identified DNA sensor is the nucleotidyltransferase cyclic GMP-AMP 
synthase (cGAS). Although it does not belong to the ALRs it shares some common features 
and detects cytoplasmic microbial DNA. However, cGAS has the unique feature to signal via 
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the production of a second messenger called cyclic GMP-AMP (2´3´cGAMP) that triggers the 
adapter molecule STING (9). 
An important family for detection of viral infection in the cell are the RLRs. They are  
composed of three members, namely melanoma differentiation antigen 5 (MDA5), retinoic 
acid inducible gene I (RIG-I) and laboratory of genetics and physiology 2 (LGP2)  that detect 
different viral RNAs in the cytoplasm (4).  
Although there is a great variety of PAMPs and PRRs, they all have in common that they 
activate immune responses through expression of diverse proinflammatory cytokines, 
chemokines and type I interferons which in turn results in the inhibition of the pathogen`s 
ability to replicate and the recruitment of further immune cells (4). 
1.2 RIG-I-like receptors 
Viruses do not possess an own metabolism and thus, depend on the metabolic pathways of 
their hosts. Therefore, there are no virus specific structures of lipids or sugars that could be 
utilized as PAMP. The detection of viruses within the innate immune system is highly 
dependent on specific structures and the localization of their nucleic acids that differs from 
nucleic acids from their hosts and can be used to sense their presence.  
RLRs detect viral RNA in the cytoplasm and play a pivotal role in virus recognition. Up to now 
there are three members of this receptor class known, namely RIG-I, MDA5 and LGP2 (10). 
Common features are the ATP-dependent helicase domain and the carboxy-terminal domain 
(CTD) that are responsible for binding of RNA. Additionally, RIG-I and MDA5 have an amino-
terminal caspase recruitment domain (CARD) that is essential for the interaction with the 
downstream molecule mitochondrial antiviral signaling protein (MAVS) and subsequent 
activation of the antiviral signaling cascade (11,12).   
Using synthetic RNA ligands, different studies could reveal the specific structure of RIG-I 
ligands: RIG-I binds preferentially short RNA molecules (18 to 20 bp) that have to bear a 
triphosphate on its 5´end and must be at least partially double-stranded to trigger 
downstream signaling (13,14). More recently it was found that RIG-I can also be activated by 
double-stranded RNA having a 5´ diphosphate (15). 
Specific requirements for MDA5 triggers are less well characterized besides its high affinity 
for long RNA molecules like the RNA analogon polyIC (polyinosinic:polycytidylic acid) that is 
often used to trigger MDA5 signaling. It is assumed that the lack of 2´-O-methylations and 
specific primary and secondary structures also play a certain role (16,17).   
Due to the lack of CARD domains LGP2 is not able to activate the MAVS dependent signaling 
cascade. It has a regulatory role by modulating the binding of viral RNA by RIG-I or MDA5. 
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Originally it was identified as negative regulator of RIG-I (18,19), whereas more recent 
studies also described a positive regulatory function on RIG-I and MDA5 (20–22).  
1.3 Virus detection by RIG-I-like receptors 
Due to its preference for different RNA structures RIG-I and MDA5 recognize different groups 
of viruses (23). RIG-I is known to sense viruses of the order Mononegavirales that are 
characterized by a single stranded RNA genome of negative orientation [(-)ssRNA], e.g. 
influenza virus, Ebola virus, Sendai virus and vesicular stomatitis virus (VSV) (24–26). Typical 
sensors of MDA5 are members of the family Picornaviridae bearing a positive sense ssRNA 
genome [(+)ssRNA], e.g. hepatitis A virus, encephalomyocarditis virus (EMCV) and Mengo 
virus (26,27).  
However, the detection of a virus is not exclusively limited to one of these receptors. For 
some of the (+)ssRNA viruses (e.g. Flaviviridae [hepatitis C virus, Dengue virus, West Nile 
virus]) and dsRNA viruses (reoviruses, e.g. rotavirus) both receptors have been shown to bind 
its RNA (28,29). Additionally, both receptors play a role in detection of different DNA viruses, 
like herpes viruses (e.g. herpes simplex virus-1, Eppstein-Barr virus) or adenoviruses for 
RIG-I or the vaccinia virus detected by MDA5. This needs the transcription of AT-rich viral 
sequences by the RNA polymerase III leading to RNA intermediates with a triphosphate 
moiety on their 5´ end (30,31). Although the responsible receptor for detection of many 
viruses is known, information about the precise viral RNA pattern that binds the receptor is 
often lacking or under discussion. 
In the course of replication different viral RNA species are described to be responsible for 
the activation of RIG-I. For some members of Mononegavirales (i.e. Zaire Ebola virus, Nipah 
virus) the tri-phosphorylated full-length genome was found to be the ligand for RIG-I (24,32). 
Others claim short transcripts of the 3´-leader and 5´-trailer promoter regions and so called 
DI (defective interfering) genomes to be the main trigger of RIG-I during Sendai virus 
infection (33–35). 
1.4 Replication cycle of vesicular stomatitis virus 
VSV is a widely used model virus of the family Rhabdoviridae that belongs to the order 
Mononegavirales that has the common feature of a nonsegmented (-)ssRNA genome. It is 
well known that infection with VSV triggers the RIG-I signaling pathway. However, the exact 
RNA species that activates RIG-I during VSV infection is unknown. But there is evidence that 
its detection by RIG-I depends not only on the structure of the incoming genomic RNA of VSV 
but on viral RNA species generated during the viral replication cycle in the infected cell (36).  
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The genome of VSV has a size of 11.161nucleotides (nt) that encodes for five proteins: the 
nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G) as well as for the 
viral RNA-dependent RNA polymerase (L). These genes are separated by regulatory 
intergenic regions that act as transcriptional promoters. The genome is flanked by 
untranslated regions (UTR), that are called leader at the 3´UTR and trailer at the 5´UTR. The 
leader sequence serves as a promoter for the transcription and replication (37,38). During 
transcription the polymerase generates mRNA for each gene separately. It stops transcription 
after every transgenic region before continuing with the next gene. The mRNAs are modified 
by a cap structure at the 5´ end and a polyA tail at the 3´ terminus. The first transcript that is 
synthesized is the leader-transcript and in contrast to all others is not capped or 
polyadenylated. Since the viral polymerase is highly error-prone, it does not stop at every 
intergenic region leading to so-called leader-N read-through transcripts or bi- or tricistronic 
RNAs (39,40). 
If enough N protein for encapsidation of the viral genome is synthesized, the polymerase 
switches from transcription to replication. In the process of replication, the polymerase skips 
the intergenic regions to generate a full-length antigenome. This in turn serves as template 
for replication of new full-length genomes, wherein the trailer sequence serves as a promoter 
(41). These are packed into virus particles for release of the cell and further infection.  
Not only during transcription but also during replication the polymerase is prone to errors 
which can lead to deleterious variants of the full-length genome, the so-called defective 
interfering genomes.  
1.5 Origin and types of defective interfering genomes  
Defective interfering particles are spontaneously generated incomplete virus particles that 
are formed during replication and carry an incomplete (defective) genome. The reason for 
the production of such genomes lies in the high error-prone viral polymerase that has the 
ability to skip from one template to another or within one template. This leads to incomplete 
genomes or RNAs pieced together using more than one template (42,43).  
Already 70 years ago, Henle and Henle made the observation, that inactive viral particles can 
interfere with the replication of influenza (44). Further studies by Magnus et al. could show, 
that incomplete viral particles are responsible for this phenomenon (45). He found that these 
defective viral particles are generated by undiluted passaging of the virus in embryonated 
chicken eggs. Further analyses of these incomplete viral particles lead to the following 
characteristics of the so-called defective interfering (DI) particles: they contain normal 
parental viral proteins, they contain only a part of the viral genome, they require a complete 
parental virus, the so-called helper virus for reproduction, because they provide the missing 
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proteins for replication and propagation and DI genomes interfere with the replication of the 
parental virus (46).  
Most of the viruses, RNA as well as DNA viruses, have been found to generate DI genomes 
(47). However, the best studied DI genomes are derived from (-)ssRNA viruses, which have 
allowed the classification into three types. The simplest type is deletion defection, where a 
part within the genome is missing that can be up to 90 % of the total genome. A second 
variant is the snapback defect. That occurs when the viral polymerase transcribes one part of 
the template and then continues with transcription of the new strand. This leads to formation 
of a DI with a usual 5´ end but an inverted repeat of the same terminus at the 3´ end. Due to 
complementarity of the ends, they can form hairpin structures. The third type is known as 
copyback DI genome. The replicase carries a partially synthesized strand and skips back on 
the same strand to transcribe the 5´end leading to a panhandle structure (Figure 1) (42,48). 
Because of their smaller size and their two transcriptional start sites (for copyback and 
snapback DI genome) the DI genome has a replicative advantage compared to the full 
genome, causing an accumulation of DI genomes while the titer of parental virus is 
decreasing. 
Besides their ability to interfere with the replication of the full-length viruses, DI genomes 
have been found years ago to also influence the immune response by increasing the IFN level 
(49). A main reason for that became clear in the recent years when DI genomes, especially 
copyback DIs, were found to bind to RIG-I, e.g. for Sendai virus, influenza and measles virus. 
Due to their double-stranded parts and their 5´triphosporylated terminus, they have the 
required structural features for being a RIG-I ligand (50).  
Since DI genomes were found to originate during multiple passaging at a high multiplicity of 
infection (MOI), it was believed that they are cell culture artefacts. However, the usage of 
high sensitive techniques, like deep sequencing, for detection of viral genomes, DI genomes 
have been identified in several human specimens after infection with different viruses ex vivo, 
like Dengue virus, influenza A virus and hepatitis A and C virus (51–54). Until now, it is under 
discussion what the role of the DI genomes under physiological conditions is.  
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Figure 1: Types of defective interfering genomes. Scheme of different DI genomes generated 
in the replication cycle of (-)ssRNA viruses. The description of their origin is given in the text. 
Modified from (55).  
 
1.6 RIG-I activation and signal transduction 
The activation of RIG-I is highly regulated, since spontaneous signaling can cause 
inflammatory and autoimmune diseases, which is known from patients that carry RIG-I gain-
of-function mutations (56). The tight regulation is achieved by the requirement of 
conformational changes and post-translational modifications for activation.  
In an uninfected cell RIG-I is kept in an autoinhibited state that sterically keeps the CARD 
domain sequestered by the repressor domain (57,58). This inactive form is maintained in part 
through the phosphorylation of two specific sites in the CARD domain by conventional protein 
kinase α (PKC-α) and PKC-β and by phosphorylation within the repressor domain by casein 
kinase II (59,60). Due to the conformational change upon binding of viral RNA, the inhibitory 
phospho-residues are removed. The CARD phosphorylation sites are known to be removed 
by the phosphoprotein phosphatase 1-α (PP1α) and PP1γ (61). This dephosphorylation and 
conformational change lead to RIG-I oligomerization via their CARD domain allowing the E3 
ligase TRIM25 (tripartite motif containing 25) to bind and generate K63-linked ubiquitin 
chains to the CARD domain of RIG-I (62). This further leads to the recruitment of the 
mitochondrial targeting chaperone protein 14-3-3ε, which is an essential component of the 
“translocon” leading to translocation of RIG-I to the mitochondrial antiviral signaling protein 
MAVS (63). Besides these essential molecules further ubiquitin-ligases are described to 
either enhance the signaling (e.g. Riplet, Mex3c) by generating K63-linked ubiquitination or 
to dampen the signaling by marking RIG-I for degradation with K48-linked ubiquitination 
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(e.g. RNF122, RNF125) or by removing K63-linked ubiquitin chains (e.g. CYLD, USP3) (64–
70). 
However, once RIG-I is activated the exposed and oligomerized CARD domains interact with 
the central downstream adapter molecule MAVS via their CARD domains leading to 
transduction of the antiviral signaling.  
1.7 MAVS and its activation 
Shortly after RIG-I was discovered, MAVS - also known as IPS-1 (IFN-β promoter stimulator 
protein 1) , VISA (virus-induced signaling adapter) or Cardif (CARD adapter inducing IFN-β) 
- was identified by four different groups as an essential adapter molecule for the signal 
transduction by RIG-I-like receptors (RLRs) (71–74). MAVS, a 540 amino acid (aa) containing 
protein (in humans) is composed of a CARD domain at the N-terminus, a proline-rich region 
(PRR) and a transmembrane (TM) domain at the C-terminus (Figure 2A). The TM domain 
allows the integration of MAVS mainly into the outer mitochondrial membrane (OMM) but 
was also found to localize to peroxisomes (75) and to mitochondria-associated membranes 
(MAM) (76) which are subdomains of the endoplasmic reticulum (ER). Via CARD-CARD 
interaction MAVS is activated by RIG-I or MDA5 and is thus essential for their signaling. It 
was also found that the localization in membrane is required for signaling, since the deletion 
of the TM domain abolished the ability of MAVS to transmit RLR signaling (73). Another 
requirement for MAVS activation is its ability to form homo-oligomers that subsequently lead 
to the prion-like formation of MAVS oligomers. These aggregates form a signaling platform 
for the recruitment of downstream signaling molecules.  
The first molecules associating with oligomerized MAVS are TNF receptor-associated factor 
2 (TRAF2), TRAF3, TRAF5 and TRAF6, that interact via the PRR domain of MAVS (74,77,78). 
These E3 ubiquitin ligases generate ubiquitin chains that serve as scaffold for further 
signaling molecules. Liu et al showed that the TRAF molecules act redundantly, since the 
knockout of one of these molecules do not affect the signaling (79). There are three sites 
identified in MAVS that have binding motifs for TRAF molecules, the TRAF-interacting motifs 
(TIM). The region I (aa 138-152) containing a TRAF2/3/5- and a TRAF3/6-binding motif and 
region II (aa 451-465), that has only a TRAF3/6-binding motif, were shown to be important 
for the activation of the NFκB (nuclear factor κ B) signaling branch, whereas the region III (aa 
401-450) was shown to be indispensable to activate the IRF3 (interferon regulatory factor 3) 
signaling branch (see Figure 2A) (80) .  
The interferon induction downstream of RLRs requires the activation of IRF3 or IRF7 that is 
mediated by its phosphorylation through TBK1 (TANK binding kinase 1). Therefore, TBK1 is 
an essential molecule in MAVS-mediated IRF3 signaling. However, how TBK1 is activated is 
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still a matter of debate. One model says, that NEMO (NFκB essential modulator) is recruited 
after TRAF-binding. This acts as a scaffold for further recruitment and activation of TBK1 and 
IKKε (IκB kinase ε) to the MAVS signaling complex via the adapter molecule TANK (TRAF 
family member associated NFκB activator) (81). In contrast, a recent study claims, that 
TBK1/IKKε can also be activated independently of NEMO through direct interaction with 
TRAF molecules (82). As it was for a long time assumed, IRF3 is not directly phosphorylated 
by TBK1 but needs the interaction with MAVS as well. MAVS has a specific phosphorylation 
motif that is first phosphorylated by TBK1 and IKKε. This in turn leads to recruitment of IRF3 
to MAVS, which is essential for its subsequent phosphorylation by TBK1 (83). Activated IRF3 
then dissociates from MAVS and dimerizes through the phospho-binding domain before it is 
translocated into the nucleus to drive the expression of type I interferons (IFNs). 
The activation of the NFκB branch, other than for IRF3 activation, is completely dependent 
on NEMO (82). After binding of NEMO through TANK, it recruits the subunits IKKα and IKKβ. 
Together they form the classical IKK complex that is important for phosphorylation of IκBα, 
that in turn releases the subunit p50 and p65 of NFκB for translocation into the nucleus to 
drive transcription of proinflammatory cytokines such as interleukin 6 (IL-6) and IL-1β (84) 
(Figure 2B). 
Besides these essential players of the antiviral signaling via MAVS there is also a growing list 
of proteins and mechanisms that negatively or positively regulate the activity of MAVS. 
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Figure 2: MAVS and the RIG-I-like receptor pathway. (A) Schematic representation of MAVS 
with important functional domains: caspase-recruitment domain (CARD), proline-rich region 
(PRR), transmembrane domain (TM) and TRAF-interacting motifs (TIM). (B) The RLR pathway 
is activated by binding of viral RNA to RIG-I or MDA5. Subsequently, they bind to MAVS via 
CARD-CARD interaction. The activation of MAVS leads to its polymerization and recruitment of 
several interaction partners that finally leads to transcription of IRF3- and NFκB-driven genes. 
Details are described in 1.6 and 1.7.  
 
1.8 Regulation of MAVS signaling  
In contrast to RIG-I, MAVS is not a classical interferon-stimulated gene (ISG) that is 
transcriptionally regulated by IRFs. Its expression level and activity are instead controlled by 
different transcriptional, post-transcriptional and post-translational mechanisms.  
Protein phosphorylation is one well known mechanism by which protein activity is regulated, 
although for MAVS just a few phosphorylation-dependent modulations are described. The 
Polo-like kinase 1 (PLK1) was found to bind to MAVS and disrupt the binding of TRAF3 to 
MAVS thereby inhibiting the IFN induction (85). The protein kinase A (PKAC) subunits α and 
β were recently identified as further inhibitory kinases. They were shown to phosphorylate 
MAVS at threonine residue 54 (T54) to inhibit MAVS aggregation and prime it for degradation 
(86). C-Abl is a tyrosine kinase, that was described to phosphorylate MAVS and positively 
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regulate the RLR signaling. Its knockdown impaired the activation of IRF3 and NFκB (87). In 
another report the tyrosine residue 9 (Y9) was identified as an important site for antiviral 
signaling. A phosphorylation-incompetent mutant of that site was not able to induce IFN-ß 
anymore and showed highly diminished NFkB signaling. Still, the kinase that phosphorylates 
Y9 needs to be identified (88). The first phosphatase that interacts with MAVS was described 
by Xiang et al. (89). They found that the protein phosphatase magnesium-dependent 1A 
(PPM1A), that was already described to regulate IKKß and STING activity, also 
dephosphorylates MAVS as well as the TBK1/IKKε complex, thus dampening the IRF3 axis.  
Another important post-translational regulation mechanism is ubiquitination. Ubiquitination 
is mediated by E3 ligases that can generate and transfer different types of ubiquitin chains. 
The most common ones are the K63- or K48-linked ubiquitin chain. Whereas the former 
causes protein activation, the latter mediates degradation. Besides the well-described 
activating ubiquitination by TRAFs, there are many more E3 ligases known that coordinate 
MAVS activity. For example the E3 ligase TRIM31 conjugates K63-linked ubiquitin to MAVS, 
that facilitates the formation of MAVS aggregates thereby enhancing the MAVS signal (90). 
However, there are also E3 ligases described that conjugate K48-linked ubiquitin chains to 
MAVS thereby leading to its degradation, e.g. RNF125, TRIM25, MARCH5 and AIP4 (67,91–
93) and shut down of antiviral signaling.   
Since MAVS is mainly localized to mitochondria, mitochondrial proteins are also involved in 
its regulation. The first identified regulatory protein of MAVS is the nucleotide-binding 
domain and leucine-rich repeat containing family member NLRX1. It inhibits the signaling 
by preventing the CARD-CARD interaction of RIG-I and MAVS (94). Since NLRX1 was found 
to be expressed in the mitochondrial matrix (95), it is not clear how it exerts its function. The 
translocase of outer membrane 70 (TOM70) is a positive regulator and facilitates the 
recruitment of TBK1/IRF3 to the mitochondria (96).  
Moreover, proteins involved in mitochondrial dynamics can influence MAVS activity. 
Mitofusin 2 (Mfn2) is important for mitochondrial fusion and directly interacts with MAVS 
thereby inhibiting the downstream signaling (97). Whereas it is unclear if this function of 
Mfn2 is linked to its function in mitochondrial fusion another study provide evidence that 
mitochondrial fusion enhances RLR signaling. Here, it was shown that infection with Sendai 
virus induced elongation of the mitochondria and upon knockdown of Mfn1 and OPA1 (optic 
atrophy protein 1), both mediators of mitochondrial fusion, the activation of IFN-ß and NFkB 
signaling was inhibited. The opposite was true upon knockdown of Drp1 (dynamin 1 like 
protein) and Fis1 (mitochondrial fission 1 protein) that are important proteins for 
mitochondrial fission (98).   
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Besides mitochondrial dynamics, also metabolic functions are involved in antiviral signaling, 
like the production of reactive oxygen species (ROS) and the mitochondrial membrane 
potential (Δψm). Koshiba et al. showed that Mfn1/Mfn2 double knockout cells had impaired 
Δψm and reduced antiviral signaling. Furthermore, they could show that chemically 
disrupting the Δψm with the protonophore CCCP had the same negative effect (99). Since the 
aforementioned fission and fusion process also influences the membrane potential it is 
unclear, what initially causes the effect.  
The Δψm is also linked to the production of ROS, which was found to regulate RLR signaling 
as well. The treatment with antioxidant compounds reduced RLR signaling, whereas an 
increase of ROS production induced by rotenone increased the induction of interferon type I 
(100). In line with this, Soucy-Faulkner et al. found that ROS is required to active IRF3 after 
Sendai infection (101). Furthermore, the mitochondrial protein COX5B (cytochrome C 
oxidase 5B) that is part of the electron transport chain was described to directly interact with 
MAVS. The deletion of this protein lead to enhanced MAVS-dependent signaling, whereas 
overexpression caused its suppression. This effect was linked to the negative regulatory 
function of COX5B on ROS production (102). The group further showed that COX5B interacts 
with Atg5 (autophagy related 5), a protein that is important for autophagic signaling, upon 
MAVS activation. Signal enhancement or repression was observed after Atg5 knockdown or 
overexpression, respectively. This suggests that the negative regulation is mediated by 
autophagy. 
Autophagy is also strongly linked to ROS production and mitochondrial dynamics. This is a 
process by which damaged organelles are removed from the cell, and in case of mitochondria 
specifically known as mitophagy. There are several autophagy-related proteins known to 
regulate RLR signaling. In line with Zhao et al. (102), another study showed that the knockout 
of Atg5 leads to increased MAVS expression and RLR signaling. The authors concluded that 
the loss of autophagy leads to accumulation of damaged mitochondria that increases the ROS 
production, thus the mitochondrial homeostasis is important for proper signaling (100). Sun 
et al. further showed that MAVS is directly involved in maintaining mitochondrial 
homeostasis via autophagy. They identified the LC3 interacting region (LIR domain) Y9xxI12 
in MAVS and demonstrated direct interaction of LC3 via this domain (103). LC3 is a main 
player in autophagy and essential for the formation of autophagosomes. The same finding 
was made by another group, that specifically showed this interaction in microglial cells. They 
further found that the LC3-MAVS interaction is mediated by phosphorylation of MAVS via c-
Abl (104). Ubiquitination is also a process that is highly important to transmit autophagic 
signaling. Recently, the autophagy receptor CALCOCO2 was shown to be recruited to 
ubiquitinated MAVS for autophagic degradation. Here a K27-linked ubiquitin chain was 
catalyzed by MARCH8 that was recruited to MAVS via BST2, a protein known to be a viral 
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restriction factor (105). All in all, autophagy is described as an important mechanism to avoid 
excessive inflammation by downregulating MAVS signaling.  
Another specific feature of MAVS is its polycistronic mRNA allowing the translation of distinct 
proteins from a single mRNA. Brubaker et al. identified a truncated variant of MAVS, the so 
called miniMAVS, that is translated from the alternative start codon Met142 and has a size of 
approximately 50 kDa (106). By overexpression of miniMAVS together with full-length (FL) 
MAVS a decrease of IFN induction was observed. Whereas the formation of MAVS aggregates 
was unaffected, the authors claim that interaction of miniMAVS with TRAF molecules causes 
the negative regulation: The more TRAF molecules bind to miniMAVS, the less is available 
for binding of FL-MAVS and subsequent signal transduction. In contrast, another study 
describes truncated MAVS to be important for MAVS aggregation. Besides miniMAVS, they 
identified four more truncated MAVS variants, that are all capable for homotypic interaction 
of their TM-domain with the TM-domain of FL-MAVS. This interaction is important for the 
homeostasis of MAVS by preventing spontaneous aggregation of FL-MAVS (107). However, 
both studies imply a negative regulatory function of miniMAVS. Moreover, miniMAVS also 
displays an inhibitory function on the TLR3 pathway. They could show, that silencing of 
MAVS enhanced TLR3-driven signaling, whereas overexpression of miniMAVS lead to 
downregulation, indicating that there is crosstalk between these two antiviral signaling 
pathways (108) (see Figure 3). 
A strong crosstalk also exists between the DNA-sensing pathway via STING and MAVS. Upon 
activation of RIG-I, STING interacts with the RIG-I-MAVS complex and facilitates the 
recruitment of TBK1 (109,110). This interaction was known before the actual function of 
STING, the downstream adapter of the DNA sensor cGAS, was identified.  
There are many regulatory proteins and mechanisms known that orchestrates the antiviral 
immune response upon MAVS activation. This makes clear, that tight regulation of this 
signaling is necessary to integrate different signaling branches to produce an adequate 
antiviral immune response that restricts viral replication but also limits inflammation.  
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Figure 3: Regulation of MAVS activation. Different mechanism of the regulation of MAVS 
activity are shown. Arrows in green and red show positive and negative regulation, respectively. 
The details are described in section 1.8.  
 
1.9 RIG-I-like receptor signaling in health and disease 
The importance of a tight RLR signaling regulation becomes evident in patients with different 
mutations in RIG-I or MDA5. Regardless of viral infections, an abnormal activity of RIG-I or 
MDA5 can lead to autoimmune diseases. For MDA5 several gain-of-function mutations are 
described, that lead to hyperactive variants of MDA5 that causes different interferonopathies 
such as Aicardi-Goutières syndrome (AGS), systemic lupus erythematosus (SLE) and 
Singleton-Merten syndrome (SMS) (111,112). A gain-of-function mutation in RIG-I has been 
found to be causative for an atypical SMS (113). Vice versa there are mutations in MDA5 
described that cause a loss-of-function and result in immunodeficiency disorders leading to 
higher susceptibility to respiratory viral infection such as respiratory syncytial virus (RSV) 
and rhinovirus (114–116). For MAVS, there is so far one loss-of-function mutation described 
that was found to be associated with lower IFN production in SLE patients because of 
inhibition of ROS-induced self-oligomerization of MAVS (117,118). 
The RLR pathway is also an interesting target for cancer immunotherapy. Triggering this 
pathway in tumor cells can lead to direct IFN-independent tumor cell killing as well as to IFN-
dependent activation of adaptive immunity. Although RLR ligands are not yet approved for 
treatment of cancer, there are many studies hinting towards a promising strategy to fight 
cancer. Besides using pIC as immunostimulatory agent, different siRNAs with a 
5´triphosphate moiety have been tested (119). These bifunctional molecules are able to 
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induce RLR-dependent signaling as well as to silence a specific oncogene, as it was shown 
for TGF-β1 to treat pancreatic cancer or with an bifunctional siRNA against Bcl-2 to treat 
melanoma in mice (120). Moreover, oncolytic viruses are attractive tools to trigger RLR-
dependent signaling in tumor cells. These viruses selectively replicate in tumor cells and are 
able to directly induce tumor cell lysis and also to induce adaptive antitumor immunity.  T-Vec 
(talimogene laherparepvec), a genetically engineered herpes simplex virus additionally 
encoding GM-CSF to further stimulate the immune system, is the first approved oncolytic 
virus to treat malignant melanoma (121). Another promising oncolytic vector is VSV, because 
it has a rapid replication cycle and is naturally selective for tumors, since it can only replicate 
in cells defective for IFN signaling, a typical feature of many tumor cells. Although many 
variants of engineered VSV have been successfully tested in the mouse model, there are still 
safety issues to overcome, because the wt VSV is neurotrophic and can cause encephalitis in 
humans (122).  
1.10 Analysis of protein-protein interaction 
The identification and characterization of protein-protein interactions (PPIs) is a major 
challenge in cell biology. PPIs are fundamental to understand biological processes and 
intracellular signaling pathways and help in understanding diseases. Conventional methods, 
like co-immunoprecipitation (IP) and yeast-two-hybrid (Y2H) assays have been used for years 
and most interaction networks that are known have been identified or verified by these 
methods.  
In co-immunoprecipitation assays the protein of interest is isolated from a whole cell lysate 
with a specific antibody coupled to a matrix like agarose, sepharose or magnetic beads. To 
increase binding specificity the protein of interest is often marked with a tag (e.g. flag, myc, 
His) that is then used as the antigen for the IP. The IP can also be performed with purified 
proteins in a cell-free assay or after overexpression in a suitable cell line and cell lysis. The 
precipitated proteins can be analyzed by Western blot for expected proteins or via Mass 
spectrometry to identify all proteins in the complex. This method can be also applied to 
identify bound DNA (ChIP) or RNA (RIP) that just need another purification step after IP. 
Although this method is used broadly, it has some major limitations. It relies on in vitro 
handling of cell extracts and only allows the detection of high-affinity PPIs that are still intact 
after cell lysis. Conversely, after cell lysis new complexes can form, that are not present in 
living cells, leading to false positive candidates (123). 
First described in 1989, the Y2H system is a method that is used for detection of two 
interacting proteins in the living yeast cell. Here, the two putative interactors are fused to 
different subunits of a transcription factor. Only when these proteins come in close proximity, 
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the transcription factor becomes functional and drives the expression of a reporter gene, e.g. 
LacZ. This method is extensively used in screening approaches by using a set of prey and a 
set of bait proteins that are systematically co-expressed. This method is suitable to detect 
direct physical interactions between two proteins. But, as for IP, does not represent a 
physiological situation, since modified proteins are used, that are most often not originated 
from the yeast (124).  
The idea of tagging proteins to detect their interaction was also used for newly developed 
methods like fluorescence resonance energy transfer (FRET). Here, a prey and bait protein 
are fused to two different fluorescence tags with overlapping emission/excitation spectra. If 
both proteins are in close vicinity, the energy from the donor fluorophore is transferred to 
the acceptor fluorophore and can be visualized via confocal microscopy in living cells. This 
is similar to bioluminescence resonance electron transfer (BRET) that uses the combination 
of a fluorophore and luciferase. Other modifications of this method use split proteins like 
split-ubiquitin or split-GFP. Here the N-terminus and the C-terminus are fused to different 
proteins of interest and only if they come together the functional protein (Ubiquitin or GFP) 
is detectable. An advantage of these methods is, that interactions in the living cell can be 
detected. These techniques however are better suitable for verification of protein 
interactions, rather than for identification of new interactors. It further needs the modification 
of two proteins of interest, which bares the danger to artificially introduce functional and 
structural changes (125).  
A new class of method for detection of PPIs is the enzyme-mediated proximity-based labeling. 
The basic principle is that an enzyme catalyzes a reaction that forms reactive biotin and can 
then covalently bind to nearby proteins. The main advantages are that these techniques are 
unbiased and can be applied to living cells, catching a physiological situation. Since all 
interacting proteins are tagged with biotin within the living cell, the cells can then be lysed 
with harsh condition and biotinylated proteins can specifically be enriched by Streptavidin 
pull-down, thus enabling for the detection of weak and transient interactors.  
There are two new methods for this type of PPI detection. On the one hand it is the so called 
BioID, that uses a variant of the bacterial enzyme BirA and the APEX-mediated labeling, that 
uses an engineered ascorbate peroxidase (APEX). The main difference of these approaches 
is the enzyme kinetic. Whereas BirA needs to be active for 16 h the biotinylation reaction of 
APEX takes place in just one minute. For BirA, this leads to a history of proteins that 
interacted with the protein of interest in this time frame, whereas APEX is suitable to give a 
snapshot of a proteome at a defined time point (126,127). 
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1.11 Proximity-based APEX-mediated live cell labeling 
The method of APEX-mediated labeling in living cells was first described by Rhee et al. in 
2013 showing a highly specific proteome mapping of the mitochondrial matrix (128). The 
new striking feature of this method is the combination of spatial and temporal resolution of a 
proteome in the living cell. 
APEX is derived from a 28 kDa cytosolic plant peroxidase. It was first discovered as a suitable 
tool for staining in electron microscopy. Here, it catalyzes the H2O2-dependent 
polymerization of diamobenzidine (DAB) for EM contrast, the same reaction that was usually 
induced using the horse radish peroxidase (HRP). One disadvantage of the HRP is that it is 
inactive when expressed in the cytosol, which could be overcome by APEX, showing activity 
in all cellular compartments (129).  
Besides DAB, APEX can oxidize several phenol derivates to phenoxyl radicals in the presence 
of H2O2, that covalently react with electron-rich amino acids (i.e. Tyr, Trp, His, and Cys). 
These highly reactive radicals have a very short life-time of < 1 ms, allowing the covalent 
reaction to be restricted to the small labeling radius (< 20nm) that these molecules can reach 
by diffusion during their reactive life time (128). By using biotin-phenol as a substrate, 
proteins in the near surrounding of APEX get biotinylated.  
In the mentioned proof-of-principle study Rhee et al. showed by targeting APEX to the 
mitochondrial matrix, that they were able to specifically label matrix proteins. The MS data 
of biotinylated proteins revealed, that 80 – 90% of the described matrix proteome was 
detected. They could further detect proteins, that had not been described as matrix protein 
yet (128).  
Rhee et al. established the following workflow for this method: The first requirement is a 
fusion protein of APEX with either a specific targeting sequence (e.g. nucleus, mitochondrial 
matrix, OMM) or with a defined protein of interest. After expression of the fusion protein, the 
cells are incubated with biotin-phenol for 30 min. To activate the APEX-mediated 
biotinylation H2O2 is added. Since APEX possesses a fast kinetic, 1 min incubation was found 
to be sufficient. Afterwards the reaction is immediately stopped by removing the H2O2-
contaning medium and addition of antioxidants (sodium ascorbate, Trolox and sodium azide). 
The biotinylated proteins can then be visualized by confocal microscopy or Western blot or 
they can be purified with streptavidin beads for MS analysis (130).  
In a following study they used directed evolution to screen for a more sensitive variant of 
APEX and found that a single mutation (A134P) strongly increased APEX´ activity (APEX2) 
(131). This variant was used in further studies and also in the present thesis.  
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Up to now, this method was used in different settings, most often to analyze a proteome of a 
subcellular compartment, like the mitochondrial intermembrane space (IMS), OMM, 
mammalian cilia, the Golgi proteome in yeast or mammalian ER-plasma junctions (132–136). 
A more recent study used APEX for the first time to resolve a protein network. They fused a 
G-protein-coupled receptor (GPCR) to APEX and were able to track the dynamics and 
interactors of this receptor in a spatially and temporally-dependent manner (137). Another 
study could recently show, that APEX also works in the extracellular space to identify specific 
interaction partners during signaling. They fused the enzyme to FGF1 (fibroblast growth 
factor 1) and could identify two new receptors of this protein (138). Another interesting 
advancement of this method is the combination with the CRISPR/Cas9 system. A catalytically 
dead Cas9, that is still able to target a specific DNA locus but does not cut the DNA, was fused 
to APEX. This allowed the identification of proteins binding to specific DNA sites and is a 
promising alternative to the conventional ChIP approach (139).  
1.12 Objectives and aims 
Activation of the RLR pathway is highly important to induce a proper immune response 
against many clinically relevant viruses. The RLR-induced response is tightly controlled since 
an inadequate response can allow an unlimited spread of the invading virus while an 
exaggerate response can lead to excessive inflammation causing autoimmunity. RLR ligands 
are under development as anti-tumor agents and vaccine adjuvants and gain-of-function 
mutations in the RLR pathway have been identified as the cause of inborn autoinflammatory 
syndromes. A better understanding of the characteristics of RNAs that trigger an RLR signal 
physiologically and of the factors that modulate and terminate signal transduction will help 
to optimize the therapeutic manipulation of the RLR pathway. 
In the presented thesis two of these aspects were addressed to better understand the RLR 
signaling pathway. In the first part, the project aims to characterize natural ligands in the 
replication cycle of the model virus VSV that trigger RIG-I. Preliminary studies in our group 
had found that a specific defective interfering genome bound to RIG-I during VSV infection. 
Here, the present study continued and addressed the following questions: 
1. Is the DI genome indeed detectable during VSV infection and what is the kinetic of DI 
genome production? 
2. Is the DI genome the trigger of RIG-I activation and how does it influence the immune 
response? 
3. Are there additional ligands for RIG-I, if the virus stock is free of DI genomes and does 
the depletion of DI genomes have an impact on the immune response? 
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The second part of the thesis focused on MAVS, the key player in the RLR pathway, and 
aimed to identify new interaction partners of this molecule and thereby characterize new 
regulatory mechanisms of the RLR signaling pathway. To achieve this goal the method of 
APEX-mediated proximity labeling of proteins was used, that enables the mapping of a 
proteome in living cells in a spatially and time-restricted manner. The experimental setup 
thereby aimed to label proteins in the proximity of MAVS in the steady state and after 
triggering of the pathway with an RLR ligand. Analysis of these MAVS proteomes by mass 
spectrometry should reveal candidate proteins that interact directly or indirectly with the 
MAVS-complex upon RLR activation. Specifically, the study thereby tackled the following 
questions: 
1. Is there a fusion protein of MAVS and APEX that is suitable in terms of protein activity 
and specificity? 
2. Since APEX is localized at the cytosolic part, is the biotinylation restricted to 
mitochondria-associated proteins? 
3. Does APEX-MAVS fusion protein label MAVS interaction partners after signal 
activation? 
4. Are there significantly altered biotinylated proteins detectable in MS after signal 
activation? 
5. If new candidate proteins can be detected, do they play a role in MAVS signaling and 
what is their function? 
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2 Material and methods 
2.1 Material 
2.1.1 Technical equipment 
Alpha Imager HP    Alpha Innotech (San Leandro, USA) 
ChemiDoc Imaging system   Bio-Rad (Munich, DE) 
TCS SP5 confocal microscope  Leica (Wetzlar, DE) 
LightCycler 480    Roche (Mannheim, DE) 
NanoPhotometer    Implen (Munich, DE) 
Digital Sonifier 450    Branson Ultrasonics (Danbury, USA) 
Trans Blot Cell    Bio-Rad (Munich, DE) 
2.1.2 Kits 
Clarity Western ECL substrate  Bio-Rad (Munich, DE) 
DCTM protein assay    Bio-Rad (Munich, DE)  
ECL Western blotting substrate  Thermo Scientific (Waltham, USA) 
GeneJET Plasmid Miniprep kit  Thermo Scientific (Waltham, USA) 
Human IL-6 ELISA set   BD Biosciences (San Diegeo, USA) 
 Human IP-10 ELISA set   BD Biosciences (San Diego, USA) 
 In-Fusion HD cloning kit   Clontech (Mountain view, USA) 
 miRNeasy kit     Qiagen (Hilden, DE) 
 Total RNA kit     VWR (Radnor, USA) 
Zymoclean Gel DNA Recovery  Zymo Research (Irvine, USA)  
2.1.3 Chemicals 
 Agarose     Biozym Scientific (Oldendorf, DE) 
Ammoniumpersulfate (APS)   Sigma-Aldrich (Steinheim, DE) 
 Biotin-phenol     Iris Biotech (Marktredwitz, DE)  
Bromphenol blue    Roth (Karlsruhe, DE) 
 Bovine serum albumin (BSA)  Roth (Karlsruhe, DE) 
 Coelenterazine H    Promega (Madison, USA) 
 Cycloheximide (CHX)   Sigma-Aldrich (Steinheim, DE) 
Ethylendiaminetetraacetic acid (EDTA)  Roth (Karlsruhe, DE) 
Flag peptide     Sigma-Aldrich (Steinheim, DE) 
Formamide     Sigma-Aldrich (Steinheim, DE) 
Glycerol     Roth (Karlsruhe, DE) 
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Glycine     Roth (Karlsruhe, DE) 
Hydrogen peroxide (H2O2)   Merck (Darmstadt, DE) 
Magnesium chloride    Sigma-Aldrich (Steinheim, DE) 
 Methanol     Merck (Darmstadt, DE) 
 β-Mercaptoethanol (BME)   Bio-Rad (Munich, DE) 
 Milk powder     Roth (Karlsruhe, DE) 
 Mowiol-488     Roth (Karlsruhe, DE) 
 Nonidet P-40 (NP-40)   Fluka Biochemika (Buchs, CH) 
 Paraformaldehyde (PFA)   Sigma-Aldrich (Steinheim, DE) 
Passive lysis buffer (5x)   Promega (Madison, USA) 
Polybrene     Sigma-Aldrich (Steinheim, DE)  
Protease Inhibitor Cocktail   Sigma-Aldrich (Steinheim, DE) 
Sodium ascorbate    Sigma-Aldrich (Steinheim, DE) 
Sodium azide (NaN3)    Sigma-Aldrich (Steinheim, DE) 
Sodium chloride (NaCl)   Roth (Karlsruhe, DE) 
Sodium deoxycholate   Sigma-Aldrich (Steinheim, DE) 
 Sodium dodecyl sulfate (SDS)  Roth (Karlsruhe, DE) 
Sodium fluoride (NaF)   Sigma-Aldrich (Steinheim, DE) 
Sodium hydroxide (NaOH)   Roth (Karlsruhe, DE) 
Sodium orthovanadate (Na3OV4)  Sigma-Aldrich (Steinheim, DE) 
 Sodium pyruvate    Sigma-Aldrich (Steinheim, DE) 
Rotiphoresis Gel 30 (37,5:1)   Roth (Karlsruhe, DE) 
Tetramethylethylendiamine (TEMED) Roth (Karlsruhe, DE) 
Trichlorethanol    Sigma-Aldrich (Steinheim, DE) 
Tris hydroxymethylaminomethan (Tris) Roth (Karlsruhe, DE) 
TRIS hydrochloride (Tris-HCl)  Roth (Karlsruhe, DE) 
Triton X-100     Sigma-Aldrich (Steinheim, DE) 
Trolox      Sigma-Aldrich (Steinheim, DE) 
 Tween 20     Roth (Karlsruhe, DE) 
2.1.4 Solutions and media for cell culture 
Dulbecco´s Modified Eagle Medium  Sigma-Aldrich (Steinheim, DE) 
 (DMEM) 
 Fetal calf serum (FCS)   Gibco Products (Grand Island, USA) 
L-Glutamine     Sigma-Aldrich (Steinheim, DE) 
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Opti-MEM     Gibco Products (Grand Island, USA) 
 Penicillin-Streptomycin   Lonza (Basel, CH) 
Phosphate-buffered saline (PBS)  Sigma-Aldrich (Steinheim, DE) 
RPMI      Sigma-Aldrich (Steinheim, DE) 
Trypsin (10x)      Lonza (Basel, CH) 
2.1.5 Antibiotics  
Blasticidin      Invivogen (San Diego , CA, USA) 
Doxycycline     Sigma-Aldrich (Steinheim, DE) 
Geneticin (G418)    Invivogen (San Diego , CA, USA) 
Puromycin     Invivogen (San Diego , CA, USA) 
 Tetracycline hydrochloride   Sigma-Aldrich (Steinheim, DE) 
2.1.6 TLR agonists and cytokines 
 Poly(I:C), HMW    Invivogen (San Diego , CA, USA) 
 Macrophage colony-stimulating factor  Miltenyi Biotech (Bergisch Gladbach, DE) 
(M-CSF)   
2.1.7 Transfection reagent 
 TransIT X2     Mirus Bio (Madison, USA) 
 Lipofectamine 2000    Thermo Scientific (Waltham, USA) 
 RNAimax     Thermo Scientific (Waltham, USA) 
2.1.8 Enzymes 
T7 Endonuclease    New England Biolabs (Ipswich, USA) 
Phusion DNA polymerase   New England Biolabs (Ipswich, USA) 
RevertAid H Minus Reverse Transcriptase  Thermo Scientific (Waltham, USA) 
BbSI      New England Biolabs (Ipswich, USA) 
Fast Alkaline Phosphatase (AP)  Thermo Scientific (Waltham, USA) 
T4 polynucleotide kinase   New England Biolabs (Ipswich, USA) 
RiboLock RNAse Inhibitor   Thermo Scientific (Waltham, USA) 
2.1.9 Dyes 
DNA loading dye (6x)   Thermo Scientific (Waltham, USA) 
DNA stain G     Serva (Heidelberg, DE) 
Hoechst 33342    Pierce Bioscience (Bonn, DE) 
MitoTracker Red CMXRos   Thermo Scientific (Waltham, USA) 
Trypan blue     Lonza (Basel, CH) 
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2.1.10 Molecular weight markers 
PageRuler Plus prestained protein  Thermo Scientific (Waltham, MA, USA) 
Ladder (10-250 kDa)  
RNA molecular weight marker,  Roche (Mannheim, DE) 
DIG labeled (0.5 -10 kb)      
TriDye 2-log DNA ladder (0.1-10 kb) New England Biolabs (Ipswich, USA) 
2.1.11 Beads for pull-down 
 Sepharose CL-4B    Sigma-Aldrich (Steinheim, DE) 
 Anti-flag M2 affinity gel   Sigma-Aldrich (Steinheim, DE) 
Pierce Streptavidin magnetic beads  Thermo Scientific (Waltham, USA) 
2.1.12 Buffer and solutions 
 Lysis buffer 
Lysis buffer for flag-IP 20 mM Tris HCl (pH 7.5), 150 mM NaCl, 
0.25%NP-40, 1.5 mM MgCl2, 1 mM NaF, 400 
U/ml RiboLock RNase inhibitor, protease 
inhibitor cocktail (1:100) 
Lysis buffer for streptavidin      
pull-down 
50 mM Tris (pH 7.5), 150 mM NaCl, 0.1% SDS, 
0.5% sodium deoxycholate, 1% Triton X-100, 
10 mM NaN3, 10 mM sodium ascorbate, 5 mM 
Trolox, protease inhibitor cocktail (1:100)    
RIPA buffer 50 mM Tris HCl (pH 8.0), 150 mM NaCl, 1% 
Triton X-100, 0.05% sodium deoxycholate, 
10 mM EDTA, 2mM Na3OV4, protease inhibitor 
cocktail (1:100)    
Erylysis buffer  166 mM NH4Cl, 0.29 mM KHCO3, 3.4 mM 
EDTA, adjust to pH 7.2 
 
SDS-PAGE and Western blot 
TBS-T 50 mM Tris (pH 7.6), 150 mM NaCl, 
0.1%Tween 20  
Stacking buffer (4x) 0.5 M Tris (pH 6.8), 0.1% SDS, 0.01% 
bromophenol blue 
Separation buffer (4x) 1.5 M Tris (pH 8.8), 0.1% SDS  
Running buffer 25 mM Tris, 200 mM glycine, 0.1% SDS 
Transfer buffer 25 mM Tris, 200 mM glycine, 20% methanol 
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Loading dyes 
Laemmli buffer (6x) 300mM Tris HCl (pH 6.8), 60% glycerol, 12% 
SDS, 0.03% bromophenol blue, 5% BME 
RNA loading dye (1,5x) 98% formamide, 0.025% bromophenol blue, 
50 mM EDTA 
 Substrates 
Firefly-luciferase substrate 20 mM tricine, 2.67 mM magnesium sulfate 
heptahydrate, 0.1mM EDTA (pH 8.0), 33.3 mM 
DTT, 0.53 mM ATP, 270 μM Acetyl-coenzyme A, 
131.6 μg/ml Luciferin, 5 mM NaOH, 0.265 mM 
magnesium carbonate hydroxide 
2.1.13 Antibodies  
Antibody      Dilution Supplier 
 WB IF  
Primary antibodies    
Mouse anti-Cas9 1:1000  Cell signaling (Cambridge, UK) 
Mouse anti-GAPDH 1:30000  Merck Millipore (Darmstadt, DE) 
Mouse anti-MAVS (E-3) 1:1000 1:200 Santa Cruz (Santa Cruz, USA) 
Mouse anti-Phospho-IκBα 
(Ser32/36) 
1:1000  Cell signaling (Cambridge, UK) 
Mouse anti-RIG-I (Alme-1) 1:1000 1:100 Adipogen (San Diego, USA) 
Rabbit anti-flag 1:1000 1:100 Sigma-Aldrich (Steinheim, DE) 
Rabbit anti-NAK (TBK1) 1:500 1:100 eBioscience (Waltham, USA) 
Rabbit anti-Phospho-IRF3 
(Ser396) 
1:500  Cell signaling (Cambridge, UK) 
Rabbit anti-Phospho-TBK1 
(Ser172) 
1:500  Cell signaling (Cambridge, UK) 
Rabbit-anti-TRAF3 1:500  Santa Cruz (Santa Cruz, USA) 
Rabbit-anti-UBASH3B 1:1000  Abcam (Cambridge, UK) 
Secondary antibodies 
Alexa Fluor 488 goat anti-mouse  1:400 Thermo scientific (Waltham, USA) 
Alexa Fluor 488 goat anti-rabbit   1:400 Thermo scientific (Waltham, USA) 
Alexa Fluor 568 goat anti-mouse   1:400 Thermo scientific (Waltham, USA) 
Alexa Fluor 568 goat anti-rabbit  1:400 Thermo scientific (Waltham, USA) 
Alexa Fluor 647 goat anti-mouse  1:400 Thermo scientific (Waltham, USA) 
Alexa Fluor 647 goat anti-rabbit  1:400 Thermo scientific (Waltham, USA) 
Goat anti-mouse IgG-HRP 1:3000  Bio Rad (Munich, DE) 
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Goat ant-rabbit IgG-HRP 1:3000  Bio Rad (Munich, DE) 
Streptavidin-FITC  1:400 BD Bioscience (Franklin Lakes, USA) 
Streptavidin-HRP 1:1000  Jackson ImmunoResearch 
(Pennsylvania, USA) 
2.1.14 Cell lines 
1205 Lu cells    provided by Dr. Robert Besch (LMU, Munich) 
HEK293T    ATCC (Manassas, USA) 
PlatA      Cell biolabs (San Diego, USA)  
HEK-Flip-In (Flp-In TREXTM-293)  Invitrogen 
HEK-flag-RIG-I modified Flp-In TREXTM -293 with flag-RIG-
containing pcDNA5 (frt-to) under Tet-inducible 
promoter 
Fibroblasts    provided by Prof. Ania Muntau (LMU, Munich) 
 
2.1.15 Plasmids  
Table 1: List of plasmids. All plasmids used in the thesis are listed with backbone vector, promoter and 
important characteristics. 
Name  Vector   Promoter Characteristics 
Luciferase assay   
   RIG-I pcDNA5/FRT
/TO 
CMV  
   MAVS pcDNA3.1 CMV  
   TBK-I pcDNA3 CMV  
   IRF3-5D pcDNA3.1 CMV Constitutively active variant of 
IRF3; Mutations: S396D, S398D, 
S402D, T404D, and S405D 
   UBASH3B pcDNA3.1 
(Zeo) 
CMV Flag at N-terminus 
   UBASH3B-     
   H391A 
pcDNA3.1 
(Zeo) 
CMV Phosphatase-dead mutant of 
UBASH3B with point mutation 
H391A; flag at N-terminus 
   p125-firefly- 
luciferase  
pGL3 p125 (IFNβ) Reporter plasmid; Firefly luciferase 
expression controlled by IFNβ 
promoter 
   pRL-TK-Renilla pRL HSV-thymidine 
kinase (TK) 
Control reporter; Renilla luciferase 
expression controlled by TK 
promoter; purchased from 
Promega 
APEX constructs   
   APEX2-NES pcDNA3 CMV Expresses APEX2 with flag at the 
N-terminus fused to NES 
sequence; used for cloning of 
APEX-MAVS constructs (131) 
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   APEXNMAVS pCDNA3 CMV APEX2 fused to the N-terminus of 
MAVS 
   APEX84MAVS pcDNA3 CMV APEX2 with flag at N-terminus or 
not fused into MAVS at AA 84 
   APEX264MAVS pcDNA3 CMV APEX2 with flag at N-terminus or 
not fused into MAVS at AA 264 
    APEX510MAVS pCDNA3 CMV APEX2 with flag at N-terminus or 
not fused into MAVS at AA 510 via 
the linker N`GGAAS`C 
   APEX-TM pcDNA3 CMV APEX2 with flag at N-terminus 
fused to the TM domain of MAVS 
(AA 510) via the linker N`GGAAS`C 
   Mito-APEX pCDNA3 CMV Expresses APEX fused to 
mitochondrial localization site 
(128) 
   APEX510MAVS pMXs-Puro 5´LTR derived 
from MMLV 
Retroviral expression of 
APEX510MAVS 
   APEX-TM pMXs-Puro 5´LTR derived 
from MMLV 
Retroviral expression of APEX-TM 
Reconstitution    
   UBASH3B pLVX-Tight-
Puro 
P-tight, Tet-
responsive 
promoter 
Dox-inducible lentiviral expression 
of UBASH3B 
   UBASH3B-    
   H391A 
pLVX-Tight-
Puro 
P-tight, Tet-
responsive 
promoter 
Dox-inducible lentiviral expression 
of UBASH3B-H391A 
   tTA Advanced pLVX-Tet-On 
Advanced 
 Lentiviral vector for expression of 
tetracycline-controlled 
transcriptional activator; 
purchased from Clontech 
Other    
  hTERT  pBABE-puro 5´LTR derived 
from MMLV 
Retroviral expression of human 
telomerase reverse transcriptase; 
for generation of immortalized cell 
lines 
   eSpCas9 eSpCas9(1.1)
-2A-Puro or  
-Hygro 
CBh (CMV 
enhancer + 
chicken β-actin 
promoter) 
Expression of enhanced Cas9 with 
the respective inserted sgRNA (see 
Table 4) 
   
2.1.16 Software 
 Microsoft Office 2016  Microsoft (Redmont, USA) 
 GraphPad Prism 7   GraphPad Software Inc. (California, USA) 
 Perseus 1.5.5.3   Max Planck Institute (Munich, DE) 
 Corel Draw X7   Corel (Ottawa, Canada) 
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2.2 Methods for cell biology 
2.2.1 Cell culture 
All human cell lines were cultivated at 37°C, 95% humidity and 5% CO2 concentration in 
DMEM supplemented with 10% FCS, 1.5 mM L-glutamine and 1% penicillin-streptomycin. 
Sub-cultivation was done every 3 to 4 days. The medium was removed, and cells were washed 
once with PBS before addition of trypsin to lift the cells off the flasks surface. After 5 min 
incubation at 37°C the reaction of trypsin was neutralized by addition of cell culture medium. 
For ensuing experiments, the cells were counted with a “Neubauer” cell counter and the 
viability was controlled by trypan blue staining. The cells were plated in a defined number 
one day prior to start of the experiment.  
Format Cell line Cell number  
96-well  1205 Lu  1x104  
24-well  5x104  
6-well  3x105  
10 cm² dish  1.5x106   
20 cm² dish  5x106  
96-well HEK293T, PlatA 3x104  
6-well  8x105   
10 cm² dish  4x106   
175 cm² flask  1x107  
24-well Human fibroblasts 2.5x104  
6-well  1x105  
 
2.2.2 Virus infection 
For viral infection assays vesicular stomatitis virus (VSV) Indiana strain provided by Prof. Dr. 
Anne Krug (LMU München) was used. 
One day after plating, the cells were infected with VSV using a multiplicity of infection (MOI) 
of 1. The MOI reflects the amount of virus particles present per cell in an infection assay. The 
infection was performed in a minimal volume of Opti-MEM medium and 2 to 4 h after 
infection the supernatant was removed and replaced by growth medium. At indicated time 
points after infection (hpi) the cells were processed for further analyses. 
2.2.3 Transfection of plasmid DNA 
Plasmid DNA was transfected using TransIT X2. For transfection of 1 µg DNA 2.5 µl 
transfection reagent was used and diluted together in Opti-MEM (20 % of the total growth 
medium). The mix was incubated for 5 – 10 min at room temperature (RT) and pipetted drop-
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wise onto the cells. Expression of the indicated protein was allowed for 24 h before 
proceeding with the experiment. 
2.2.4 Stimulation with synthetic RNA molecules 
To activate antiviral signaling, the cells were stimulated with different RNAs. A commercially 
available high molecular weight polyinosininc:polycytidic acid (pIC) was used to activate 
TLR3 signaling by supplying the RNA without transfection. pIC was diluted in Opti-MEM (20 
% of the total growth medium) for a final concentration of 5 µg/ml and directly added into 
the cells medium.  
A synthetic short RNA molecule of 44 bp with a hairpin structure and a triphosphate moiety 
at the 5´end (3p-RNA) synthesized in our group by in-vitro transcription with the sequence 
3p-GCGCUAUCCAGCUUACGUA GAGCUC loop UACGUAAGCUGGAUAGCGC-5´ was used as 
a RIG-I specific stimulus. The RNA was diluted in Opti-MEM (20 % of the total cell culture 
medium) to have a final concentration of 500 ng/ml. Per 1 µg RNA 3 µl RNAimax was added 
incubated for 10 min at RT and transferred drop-wise onto the cells. The cells were stimulated 
for the indicated time points before proceeding with the experiment.  
2.2.5 Transfection of RNA isolated from VSV-infected cells 
For determination of the immunostimulatory capacity of the RNA species generated after a 
certain time after infection and replication of VSV, total cellular RNA of infected cells was 
isolated (see 2.3.12), fragmented (see 2.3.13) and re-transfected into 1205 Lu cells. This 
allowed to determine the immune response to the naked RNA without the influence of viral 
replication or viral proteins.  
1205 Lu cells plated in a 96-well were either transfected with 250 ng of the total cellular RNA 
or 10 µl of the fragmented RNA. For that the RNA was diluted in Opti-MEM in a total volume 
of 20 µl and mixed with 0.3 µl Lipofectamine RNAimax diluted in 20 µl Opti-MEM. After 
10 min at RT the transfection mix was added to the cells and 24 h later the supernatant was 
taken for determination of IP-10 release via ELISA. 
2.2.6 Transduction and generation of stable cell lines 
Transduction is the process of integrating foreign DNA sequences into the genome of cells 
via viral vectors. To do this, lenti- or retroviral expression plasmids are used, that encode the 
gene of interest within a replication-incompetent viral genome. 
For generation of viral particles derived from retroviral expression vectors, PlatA cells were 
used. This cell line is derived from HEK293T cells and stably expresses the retroviral proteins 
(gag, pol, env) needed for replication and packaging of the viral genome. Three 6-wells of 
these cells were transfected with 4 µg/ well of the retroviral expression vector. After 24 h the 
virus-containing supernatant was taken, flushed through a 0.45 µm pore-size filter, 
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supplemented with 4 µg/ml polybrene and applied to three 6-wells of the cell line to be 
modified. The PlatA cells were covered with 2 ml/well of fresh growth medium to produce 
more viral particles. After further 24 h the virus-containing supernatant was taken again and 
the transduction was repeated. 24 h after this second transduction hit the selection process 
of the cells was started. All retroviral expression plasmids used, additionally encode for 
puromycin resistance. For 1205 Lu cells and fibroblasts 2 µg/ml of puromycin was used as 
selection pressure and the medium was exchanged every second day with medium containing 
fresh antibiotics until the untransduced control cells were dead. Transduced cells were kept 
always under selection pressure with 1 µg/ml of puromycin. 
Lentiviral particles were used for generation of cell lines, that express the gene of interest 
under a doxycycline-inducible promoter. For production of viral particles, HEK293T cells 
were transfected with plasmids encoding the viral envelope proteins VSV-G (250 ng/ml) (env) 
and the plasmid dR8.91 (250 ng/ml) encoding for gag and pol along with the lentiviral 
expression plasmid (500 ng/ml) encoding the gene of interest (pLVX-tight-puro) or the 
doxycycline-controlled transactivator (pLVX-Tet-on). The expression of both plasmids in a 
cell allows the tight regulation of gene expression for the gene of interest by the doxycycline 
concentration in the cell medium.  
Both virus supernatants were taken 24 h after transfection, cleared through a 0.45 µm filter 
and supplemented with 4 µg/ml polybrene. The supernatants were mixed in a ratio of 5:1 
(pLVX-tight-puro:pLVX-Tet-on) and 2 ml were added onto a 6-well of the cells to be modified. 
In total three 6-wells were transduced per cell line and gene of interest. 48 h after 
transduction the cells were selected with puromycin (2 µg/ml) and G418 (1 mg/ml) as the 
corresponding resistance genes are encoded on pLVX-tight-puro and on pLVX-Tet-on 
respectively. After all untransduced control cells died, transduced cells were further 
cultivated under constant selective pressure with 1 µg/ml puromycin and 0.25 mg/ml G418. 
2.2.7 Tetracycline and doxycycline induction  
For induction of flag-RIG, HEK293T-flag-RIG-I and control cells HEK293T-Flip-In were 
cultivated with 1 µg/ml tetracycline.  
Cells transduced with pLVX-Tet-on inducible system were treated with the tetracycline 
derivate doxycycline in concentrations of 10 – 1000 ng/ml.  
Each antibiotic was diluted in fresh growth medium and added to the cells to allow expression 
of the induced protein 24 h before the experiment started. 
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2.2.8 Generation of knockout cell lines using the CRISPR/Cas9 system 
The CRISPR/Cas9 system is a method that allows the targeting and modification of a specific 
DNA sequence of a cells genome. The modification induced at the target site by Cas9 includes 
random insertions or deletions of bases that can lead to missense mutations, thus leading to 
the knockout (KO) of the targeted gene.  
Cas9 is a bacterial protein, that originally belongs to the bacterial adaptive immune system 
and removes foreign DNA. This endonuclease is able to bind a specific RNA sequence 
(crRNA) and cut DNA in the close surrounding. By fusing the crRNA to a target-specific 
sequence of 23 bp (sgRNA) including the specific motif `NGG`, the so-called PAM 
(protospacer adjacent motif) that is needed to activate Cas9, the enzyme cuts the DNA at the 
desired site in the genome that is complementary to the sgRNA.  
Hence, the first step for generating KO cells was to find a suitable gene-specific sgRNA. For 
this purpose, the online tool http://chopchop.cbu.uib.no/ was used. From the suggested 
sequences by the software, sgRNAs were chosen that have no or low off-target sites, that are 
in one of the early exons and that bears the nucleotide G at the 5´end, a feature needed for 
the enhanced Cas9 (eCas9) to bind highly specific. The eCas9 is an optimized Cas9 that has 
an enhanced specificity with reduced off-target effects. The cloning of the sgRNA encoding 
oligonucleotides into the eSpCas9 vector was done as described in 2.3.5. 
Per plasmid three 6-wells were transfected with 250 ng/ml of the respective sgRNA encoding 
eSpCas9 plasmid. After 24 to 48 h the selection was started by addition of fresh growth 
medium supplemented with 2 µg/ml puromycin or 10 µg/ml blasticidin, depending on the 
resistance encoded on the plasmid. The medium was replaced by fresh antibiotics containing 
medium every day until the untransfected control cells were dead. Subsequently the cells 
were washed with PBS and further cultivated in medium without the selective antibiotic.  
Either all surviving cells were expanded and used as a KO batch or they were collected and 
plated in 96-well plates in a concentration of 1 cell/well to generate single cell clones (SCC). 
These SCC were analyzed whether their DNA sequences were modified at the target site by 
T7 digestion (see 2.3.2) and positive clones were checked by Sanger sequencing for the kind 
of inserted mutation. Only clones showing one or two defined modifications that cause a 
biallelic frame shift were called a complete KO and used for further experiments.  
In the second round of generation of UBASH3B-KO cells, the SCC were analyzed by deep 
sequencing in the group of Prof. Veit Hornung (Gene center, Munich) and the online tool 
outknocker.org was used to identify SCC that have frame shift mutations on both alleles.  
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2.2.9 Induction of biotin labeling with APEX   
For the labeling, APEX-expressing cells were incubated with 500 µM biotin-phenol dissolved 
in culture medium for 30 min at 37°C, that served as substrate for APEX. To induce the APEX 
reaction 100 mM H2O2 solution was directly pipetted into the medium to a final concentration 
of 1 mM and incubated for 1 min at RT. Immediately, the medium was removed and the cells 
were strongly washed three times with PBS containing the quenchers (10 mM NaN3, 10 mM 
sodium ascorbate, 5 mM Trolox) to stop the enzymatic reaction of APEX. The labeled cells 
were either analyzed by immunofluorescence, Western blot or were processed for 
streptavidin pull-down (see 2.4.2).  
2.2.10 Live cell staining with Mitotracker  
Co-staining of mitochondria for subsequent confocal imaging (see 2.4.7) was performed with 
Mitotracker red that accumulates in living mitochondria due to its membrane potential. 
100 nm MitoTracker Red CMXRos was diluted in pre-warmed growth medium and added to 
the cells 30 min prior to fixation.  
2.2.11 Isolation and cultivation of murine bone marrow-derived macrophages  
For isolation of bone marrow cells, the femurs of the mice were used. The bones of 
UBASH3A/B-KO mice were kindly provided by the group of Prof. Christian Brandts 
(University hospital, Frankfurt). Wt mice of the same background strain C57BL/6 were used 
as controls. The bones delivered in PBS were washed in 70% Ethanol for 2 min and 
transferred into cell culture medium (RPMI supplemented with 10 % FCS, 1 mM L-glutamine, 
1% Sodium pyruvate, 1% Penicillin-Streptomycin and 100 µM BME) in a 10 cm² dish. A 
5 ml syringe was used to flush the bones with PBS through a 0.45 µm filter into a 50 ml falcon. 
The cells were centrifuged at 400 g for 5 min and the supernatant was discarded. 3 ml erylysis 
buffer was added, mixed and incubated for 3 min before PBS was added to a total volume of 
25 ml. The cells were centrifuged (400 g, 5 min) and resuspended in 1 ml cell culture medium.  
For differentiation of macrophages (BMDMs) 8x106 cells were seeded in a 10 cm² dish and 
20 ng/ml M-CSF was added. After three days the medium was completely exchanged with 
fresh medium containing newly added M-CSF.  
Three days later the cells were collected and plated in a 96-well plate with 2x104 BMDMs/well 
in medium containing fresh M-CSF. The experiment was started one day after seeding.  
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2.3 Methods for molecular biology  
2.3.1 Polymerase chain reaction  
The polymerase chain reaction (PCR) was used to either amplify gene coding cDNA 
sequences from plasmids for further sub-cloning or to amplify the target locus of sgRNA from 
total cell DNA. For quantitative reverse transcriptase PCR see 2.3.15. 
The standard PCR mix was as follows:  
Component Volume   
5x Phusion HF buffer 10 µl   
dNTPs (10 mM) 1,0 µl   
Forward primer (10 µM) 2,5 µl   
Reverse Primer (10 µM) 2,5 µl   
Phusion DNA Polymerase 0,5 µl   
Plasmid/ genomic DNA 20/ 100 ng   
H2O ad 50 µl   
 
The PCR mix did run in the thermocycler under the following standard cycling conditions: 
Step Temperature Time  
Initial denaturation  98°C 30 sec  
Denaturation  98°C 10 sec  
Annealing 60 – 72°C  
(Primer melting temp + 3°C) 
30 sec 
25 cycles 
Elongation 72 °C 30 sec/kb  
Final extension 72°C 5 min  
Hold    4°C hold  
 
 
  
2.3.2 T7 endonuclease digestion  
The T7 endonuclease is an enzyme that recognizes and cleaves mismatched DNA and was 
used to detect the presence of CRISPR/Cas9- generated genomic changes at the target site 
(see 2.2.8).  
First, an app. 500 bp DNA sequence including the sgRNA-target site was amplified via PCR 
(see 8.4). The PCR products of wt cells and of the CRISPR/Cas9 treated cell clone in question 
were pooled (10 µl each) and annealed under the following conditions in the thermocycler:  
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95°C, 10 min 
 95°C to 85°C, -2°C/s 
 85°C to 25°C, -0.1°C/s 
 4°C, hold    
Afterwards 0.5 µl T7 Endonuclease, 1x NEB buffer 2 and H2O was added to a total volume of 
30 µl. The reaction was incubated at 37°C for 1 h and analyzed for cleavage by gel 
electrophoresis.  
2.3.3 DNA gel electrophoresis 
For size-dependent separation of PCR products and digested plasmids agarose gel 
electrophoresis was performed. Depending on the size of the expected fragment 0.8 – 2 % 
agarose gels were used supplemented with 3.5 µl DNA stain per 100 ml gel. For loading, the 
samples were mixed with 1x DNA Loading dye and run at 100 V for 20 – 60 min. A 10 kb 
DNA ladder was used for size determination. 
2.3.4 Gel extraction of DNA  
To purify PCR products and digested plasmids the Gel extraction kit of Zymoresearch was 
used according to the manufacturers protocol. The resulting DNA concentration and purity 
was determined by photometric measurement in a nanodrop TM instrument. 
2.3.5 Annealing of oligonucleotides encoding sgRNA 
Synthetic DNA oligonucleotides coding for positive and negative strand of the sgRNA flanked 
by the restriction site of the enzyme BbsI (see 8.3) were ordered and annealed as follows:  
Component Volume   
Oligo-top (100 µM) 1 µl   
Oligo-bottom (100 µM) 1 µl   
10x T4 DNA ligase buffer 1 µl   
T4 Polynucleotide kinase 1 µl   
Phusion DNA Polymerase 0.5 µl   
H2O ad 10 µl   
    
The reaction was incubated in the thermocycler at 37°C for 30 min, heated up to 95°C for 
5 min before it was slowly (1°C/min) cooled down to 4°C.  
The annealed oligonucleotides were diluted 1:200 and 3 µl were used for subsequent cloning 
(see 2.3.7) into 100 ng BbSI-linearized eSpCas9 vector. 
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2.3.6 Restriction enzyme digest  
For cloning of protein coding cDNA into a vector, the vector and the purified PCR product 
were cut with two restriction enzymes to allow a subsequent ligation. The primers for the 
PCR therefore had the specific restriction sites at their 5´end.  
The standard reaction was as follows: 
Component Volume   
10x Appropriate restriction buffer 3.0 µl   
Restriction enzyme I 1.0 µl   
Restriction enzyme II 1.0 µl   
Plasmid/ PCR product 1-2 µg/ 100 – 500 ng   
H2O ad 30 µl   
The reaction was incubated for 1 – 3 h at 37°C. To avoid re-ligation of the linearized plasmid, 
1 µl FastAP (Alkaline Phosphatase) was added to the reaction mix and incubated another 
30 min at 37°C. The cut plasmid was isolated via gel electrophoresis and purified with gel 
extraction kit, whereas the digested PCR product was only column-purified.  
2.3.7 Restriction-enzyme based ligation 
To insert the cDNA of interest into a recipient vector, the digested and purified fragments 
were ligated. The vector and insert were mixed in a molar ratio of 1:3 to 1:10 (vector:insert), 
1 x ligase buffer and 1 µl ligase was added to a total volume of 20 µl. The ligation run for 4 to 
16 h at RT.  
2.3.8 In-Fusion® cloning  
The conventional molecular cloning relies on restriction sites to fuse fragments together, 
which is often a limiting factor for cloning. To overcome this, the so-called In-fusion cloning 
was performed, that works independent of any restriction site. It relies on the In-fusion 
enzyme that recognizes complementary 15 bp overhangs of the vector and insert and ligates 
it. The vector can be opened at any desired position by inverse PCR and the primers for 
amplification of the insert are designed with 15 bp overhang complementary to the linearized 
vector site.  
This method was used to generate the MAVS-APEX fusion constructs, where APEX was 
inserted into different sites of the cDNA of MAVS. The cloning was performed with the In-
Fusion® HD cloning kit according to the manufacturers protocol.  
2.3.9 Bacterial transformation 
After ligation, the plasmid DNA was introduced into bacteria for amplification of the plasmid. 
5 µl of the ligation mix was added to 50 µl of competent E. coli bacteria (used strains: DH5α 
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and MACH1) and incubated for 30 min on ice. Subsequently, the bacteria were heat shocked 
for 60 sec at 42°C and immediately put back on ice for 5 min. For recovery of the cells, 500 µl 
LB growth medium was added and incubated under shaking conditions for 1 h at 37°C. 
Afterwards the cells were plated on Agar plates supplemented with the required antibiotic.  
2.3.10 Purification of plasmid DNA 
For isolation of plasmid DNA, distinct bacterial colonies were picked and incubated in 5 ml 
LB growth medium containing antibiotic for selection at 37°C under shaking overnight. 
The grown bacteria were pelleted, and plasmid DNA was isolated with the kit GeneJET 
Plasmid Miniprep Kit from Thermofisher as described in the manufacturer´s protocol.  
2.3.11 RNA purification   
Total RNA was isolated from cells grown in a 24-well using an RNA isolation kit (Peqlab). The 
kit was used according to the manufacturer´s protocol. 
2.3.12 Phenol-chloroform-based RNA purification 
To analyze the VSV-derived RNA molecules, either after immunoprecipitation, for re-
transfection or for fragmentation, the RNA was isolated with the miRNeasy Kit from Qiagen. 
This kit is suitable to isolate high amounts of pure RNA, including small molecules >18 bp. It 
relies on the phenol-chloroform precipitation, that separates the RNA from DNA and proteins.  
The RNA isolation was performed as described in the provider´s manual.  
2.3.13 RNA fragmentation 
HEK293T cells grown in a 10 cm2 dish and infected with VSV for 24 h were lysed and RNA 
was isolated by phenol-chloroform precipitation (see 2.3.12). 8 µg of the RNA was 
supplemented with 1.5 x RNA loading dye, heated for 10 min at 70°C and immediately put 
on ice. After 10 min the RNA was separated on 0.8 % agarose gel at 60 V for 2.5 h. For size 
determination a 10 kb RNA ladder was used. After separation the RNA was cut size-
dependently into 10 fractions. 
The gel extraction of the RNA was done with the Zymoclean Gel RNA Recovery kit according 
to the manufacturer’s protocol and used for re-transfection of 1205 Lu cells (see 2.2.5).  
2.3.14 cDNA synthesis 
First-strand cDNA was generated from 200 ng of total RNA or from 10 µl re-isolated RNA 
after fragmentation and purification. For analyzes of viral genome sequences the 
transcription was performed with Random Hexamer Primer. If only mRNA transcription was 
desired, Oligo(dT) primer were used.  
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The reaction mix was composed as follows:  
Component Volume   
5x Reverse Transcriptase buffer 4,0 µl   
dNTPs (10 mM) 2,0 µl   
OligodT/ Random Hexamer Primer (10 µM) 2,0 µl   
Ribolock RNAse Inhibitor 0,5 µl   
RevertAid H Minus Reverse Transcriptase  0,5 µl   
RNA 200 ng or as required   
H2O ad 20 µl   
 
 
2.3.15 Quantitative reverse transcriptase polymerase chain reaction 
For quantification of the relative amount of specific mRNAs or of viral genome sequences, 
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was used. Relative 
gene expression was calculated as the ratio of gene of interest to the house-keeping gene 
both determined in the same sample. For all runs the standard Roche protocol for mono color 
hydrolysis probes with 45 amplifications were used and run with the LightCycler 480 
instrument. The primers and probes are listed in 8.2. The reaction mix was composed as 
follows:  
Component Volume   
2x Kappa Probe Fast mastermix 5,0 µl   
Forward primer (10 µM) 0,2 µl   
Reverse primer (10 µM) 0,2 µl   
Fluorescent hydrolysis probe 0,1 µl   
cDNA (diluted 1:3) 3,0 µl   
H2O ad 20 µl   
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2.4 Methods for protein biochemistry  
2.4.1 Immunoprecipitation of flag-RIG-I-bound RNA  
For the analysis of RIG-I bound RNA, HEK293T cells that overexpress flag-tagged RIG-I under 
the control of a tetracycline inducible promoter (HEK-flag-RIG-I) were infected with VSV. 
HEK293T cells that only bear the empty plasmid without the flag-RIG-I insertion (HEK-Flip-
In) served as negative control. For each condition 4x107 cells were plated in 4x 175 cm2 
flasks. The expression of flag-RIG-I was induced by addition of tetracycline (1µg/ml) and 24 h 
later the cells were infected with VSV (MOI 1). Another 24 h later the cells were collected, 
washed 2x with PBS and resuspended in 1 ml lysis buffer. After centrifugation (14000 g, 
15 min, 4°C) the supernatant was collected and added to 500 µl of sepharose beads, that were 
washed 2x with lysis buffer prior to usage (5000 g, 1 min). This pre-clearing step was 
performed for 1 h at 4°C with permanent rotation and should clean the lysate from all 
unspecific binding partners. The beads were centrifuged at 5000 g for 1 min and the 
supernatant was added to 250 µl of anti-flag coupled beads, that were washed 2 x with lysis 
buffer before. The incubation was proceeded for 2 h at 4°C under constant rotation. 
Subsequently, the beads were centrifuged (1000 g, 1 min) and washed 5 x with lysis buffer 
(1000 g, 30 sec). In between the beads were incubated for 5 min under rotation at 4°C. 
For elution of the flag-bound proteins and nucleic acids the beads were resuspended in 200 µl 
lysis buffer and put onto a column. To dry the beads, they were centrifuged for 30 sec at 
5000 g. The column was transferred into a clean tube and 10 µl of 3x flag-peptide and 3 µl 
RiboLock was added directly on the beads and incubated for 10 min under shaking at room 
temperature (RT). Afterwards 3 x flag-peptide was diluted in TBS (1:50) and 137 µl were 
added to the beads and again was incubated for 10 min under shaking. Due to competitive 
binding of the flag-peptide the flag-bound proteins and nucleic acids were released into the 
solution. Finally, the eluate was collected by centrifugation (4000 g, 3 min, 4°C) and used for 
further isolation of RNA (see 2.3.12) that was used for the analysis of viral genomic sequences 
by qRT-PCR. 
2.4.2 Streptavidin pull-down of APEX-biotinylated proteins 
For enrichment of proteins biotinylated by APEX, a streptavidin pull-down was performed.  
After induction of APEX-labeling for 1 min (see 2.2.9), the cells grown in a 10 or 20 cm² dish 
were washed three times with PBS supplemented with quenchers (10 mM NaN3, 10 mM 
sodium ascorbate, 5 mM Trolox). To get rid of free biotin that could interfere with streptavidin 
it was important to use a big volume of wash buffer for each wash step (20 ml per 20 cm² 
dish and 10 ml per 10 cm² dish). 
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Afterwards the cells were lysed in lysis buffer containing quencher (1 ml for 10 cm² dish and 
2 ml for 20 cm² dish). For further lysis of the nucleus and solubilization of protein aggregates 
the sample was sonicated three times for 10 sec with 10 sec break on ice. Since the quenchers 
interfere with the DCTM protein assay, reference cells were lysed in lysis buffer without 
quenchers to determine the protein concentration. The protein concentration was adjusted 
to 1 mg/ml. Prior to pull-down, the magnetic streptavidin beads were washed two times with 
lysis buffer using a magnetic rack for Eppendorf tubes. Afterwards 600 µg protein per 100 µl 
magnetic streptavidin beads were added and incubated for 1 h at RT under rotation. The 
beads were washed three times with lysis buffer.  
For further mass spectrometric analysis 3 mg protein derived from two 20 cm² dishes were 
used for pull-down and the beads were stored in 500 µl lysis buffer at -80°C. They were 
further processed by on-bead digestion in the group of Prof. Axel Imhof and analyzed via 
LC/MS. 
For Western blot analysis the pull-down was performed from 300 µg protein derived from a 
10 cm² dish. After washing the beads, they were incubated with 50 µl 3x Laemmli buffer 
containing 5 % BME for 10 min at 95 °C. Finally, the beads were removed using the magnetic 
rack. 
2.4.3 Preparation of cell lysates for Western blot 
For Western blot analysis, the cells were grown in a 6-well plate, washed once with PBS, 
lysed in 150 µl RIPA buffer and incubated for 10 to 30 min at 4°C. The lysed cells were 
collected with a cell scraper. For complete lysis, the samples were further treated by 
sonification for three times 10 sec with 10 sec break on ice.  
For detection of MAVS aggregates the samples were not sonicated, thus the pellet still 
contains unlysed cell organelles and protein aggregates. The samples were further 
centrifuged at 14000 g for 10 min at 4°C and the lysate was separated from the pellet. After 
determination of the protein concentration the lysate and pellet were incubated at 95°C with 
1x Laemmli buffer containing 5 % BME for 5 or 30 min, respectively.  
2.4.4 Determination of protein concentration  
The protein concentration of cell lysates was measured using the DCTM protein assay from 
Bio-Rad. This is a colorimetric assay based on the Lowry protein assay. The assay was 
performed according to the manufacturer´s protocol.  
2.4.5 SDS-polyacrylamide gel electrophoresis (PAGE) analysis 
Size-dependent separation of proteins by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed using 10 % separation and a 5 % stacking gels 
(for ingredients of the gels see the table below). 10 – 40 µg of protein sample (see 2.4.3) were 
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loaded on the gel and electrophoresis was performed in 1x running buffer starting with 100 V 
for 30 min followed by 150 V until complete separation. The 250 kDa PageRuler was used as 
a marker for protein size. 
Component 5 % stacking gel  10 % resolving gel  
H2O 2.26 ml  4.1 ml 
Rotiphoresis Gel 30 (37,5:1) 0.68 ml  3.3 ml 
Stacking buffer (4x) 1.0 ml  - 
Resolving buffer (4x) -  2.5 ml 
10 % APS 0.04 ml  0.1 ml 
TEMED 0.004 ml  0.004 ml 
Trichlorethanol -  0.05 ml 
  
2.4.6 Western blot 
After protein separation, a wet blot was performed. The proteins were electrophoretically 
moved from the gel onto a PVDF membrane with a pore size of 0.45 μm or 0.2 μm (for 
detection of phosphorylated proteins) in 1x transfer buffer containing 20 % methanol at 
250 mA for 2 h.  
Subsequently, the membrane was washed once in TBS-T. To avoid unspecific antibody 
binding the membrane was blocked in 5% milk or 3% BSA in TBS-T for 2 h at RT or 
overnight at 4°C. For protein staining, the membrane was probed with the primary 
antibody for 2 h, washed three times for 10 min and the HRP-linked secondary antibody 
was added for 1 h at RT. Again, the membrane was washed three times. Addition of the 
ECL substrate (ECL-Pico chemiluminescence kit or the ECL reagent of Bio-Rad) started 
the HRP reaction, that was detected with the alpha imager HP-system or Chemidoc system 
of Bio-Rad. 
2.4.7 Immunofluorescence imaging by confocal microscopy 
For confocal microscopy the cells were plated on 12 µm glass cover slips in a 24-well plate. 
The samples were fixed with 4% PFA for 10 min at RT, washed three times in PBS and 
permeabilized for 10 min in 0,1% Triton-X-100. After washing, the samples were blocked 
with 3% BSA for 2 h at RT or overnight at 4°C.  
The cells were washed again and incubated with the primary antibody diluted in PBS for 2 h 
at RT or overnight at 4°C. The secondary antibody conjugated with a fluorophore and diluted 
in PBS was added after another washing step and incubated for 1 h at RT.  
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The nucleus was stained by addition of 5 µM DNA binding dye Hoechst 33342 in PBS for 
5 min, before the cells were finally washed. The cover slips were mounted on a glass slide 
with Mowiol-488, dried overnight and imaged using a Leica TCS SP5 confocal microscope. 
2.4.8 Enzyme-linked immunosorbent assay  
The release of the cytokines IP-10 and IL-6 into the cell cultures medium was measured via 
enzyme-linked immune-sorbent assay (ELISA). The assay was performed according to the 
manufacturers protocol. For measuring cytokines, the supernatants were collected and 
measured directly or stored at -20°C.  
2.4.9 Luciferase assay 
HEK293T cells were plated in a 96-well plate. Each well was transfected with a total DNA 
amount of 219 ng complexed with 0.55 µl Lipofectamine 2000 in 20 µl Opti-MEM, incubated 
for 10 min at RT and applied dropwise onto the cells.  
The DNA amount was composed of 40 ng luciferase reporter plasmid, 4 ng renilla plasmid, 
25 ng of the signaling protein encoding plasmid and 0 – 150 ng UBASH3B encoding plasmid. 
To keep the total DNA amount constant in every condition, the empty pcDNA3 vector was 
used to stuff up the DNA amount if necessary. Each condition was done in four technical 
replicates.  
After 24 h of transfection the cells were lysed in 50 µl 1x passive lysis buffer and incubated 
10 min at RT. 20 µl/well of the lysate was then transferred onto two different white microtiter 
plates. On one plate 20 µl/well of the luciferase substrate and on the other 20 µl/well of the 
renilla substrate coelenterazine h (1:800 in H2O) was added and the luminescence was 
measured with a microplate reader.  
2.5 Statistics 
The data are presented as mean ± SEM. Statistical significance was calculated by unpaired 
Student´s t-test and kinetic data were additionally corrected for multiple comparison using 
the Holm-Sidak method (*p ≤ 0,05; **p ≤ 0,01 und ***p≤ 0,001). 
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3 Results 
3.1 Characterization of RIG-I ligands during infection with vesicular      
      stomatitis virus 
3.1.1 Detection of a specific defective interfering genome in the VSV virus stock 
Preliminary work in our group done by Andreas Linder aimed to identify the specific ligand 
of RIG-I in the replication cycle of VSV. HEK293T cells bearing a tetracycline (Tet)-inducible 
flag-tagged RIG-I or only the backbone vector Flip-In (negative control), were Tet-induced 
for 24 h followed by VSV infection for 9 h. Subsequently, the cells were lysed and a flag-IP 
was performed. The RNA was isolated and analyzed by next generation sequencing. These 
data revealed, that on the one hand in the flag-RIG condition the whole (-)ssRNA genome was 
enriched by 5-fold. On the other hand, there was a 23-fold enrichment at genomes position 
6497 until the 5´end of the genome. The trailer region in (+)ssRNA orientation showed the 
same high enrichment. These enriched sequences show typical features of a so-called copy-
back DI genome: it has a highly shortened genome and the reverse complementary trailer 
sequence at the 3´end (Figure 4A). This result raised the hypothesis that this DI genome is 
the major ligand of RIG-I (140).  
The precise analysis of the deep sequencing data allowed the reconstruction of this specific 
DI genome with a length of 4719 bp. Based on the reconstructed sequence, a specific set of 
primers was designed that binds in the trailer region and at the boarder of the reverse 
complement trailer/L-gene (Figure 4 A). A qRT-PCR assay based on these primers allowed 
the detection of this identified DI genome and to follow its expression over time after infection 
with VSV. The observed increase of the DI genome up to 24 h after infection followed the 
same kinetics as the increase of the viral N protein and the IFN-β level, reflecting transcription 
of the full-length genome and the induction of the immune response, respectively. 
Cycloheximide (CHX) is an inhibitor of translation and by blocking the translation of the viral 
polymerase indirectly also an inhibitor of viral replication. Addition of CHX completely 
abolished the increase of the mRNA of the N protein as well as of the DI genome, suggesting 
that its propagation depends on the translation of VSV-N and the viral polymerase (Figure 4 
B - D). In addition, the CHX data confirm that the interferon induction by VSV requires newly 
translated proteins and seems to depend on replication of the full-length or DI genome.  
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Figure 4: Detection of a specific DI genome in the VSV virus stock. (A) The copy-back DI 
genome was identified by deep sequencing analyses of RIG-I bound RNA. It bears a reverse 
complement trailer sequence at the 3´end, has a size of 4719 nucleotides and can be detected 
with a specific set of primer. HEK293T cells plated in 96-well plate were either treated with CHX 
(100 µg/ml) or not and infected with VSV (MOI 1). The RNA was isolated at the indicated time 
points. After cDNA synthesis the samples were analyzed via qRT-PCR for (B) the specific DI 
genome (C) the N protein of VSV and (D) the IFN-β level normalized to HPRT. Data are shown 
as mean ± SEM (n=3).  
 
3.1.2 The defective interfering genome of VSV has a major impact on the immune  
         response 
After proofing the existence of the specific DI genome in our standard VSV stock and its 
replication after infection, its impact on the immune response was determined.  
To achieve this, a virus stock was generated that is free of detectable DI genomes. A common 
method to do so, is to infect cells with a very low MOI over several passages. In fact, BHK 
cells grown in a 6-well plate were infected with an MOI of 10-6 and after 24 h the supernatant 
was collected and reused for a repetitive infection, each time with an MOI of 10-6. This 
procedure was repeated for 5 passages until the DI genome was nearly completely diluted 
out as confirmed by qRT-PCR (P5) (Figure 5 B).  
Compared to the original virus stock (P0), the infection with the stock containing low amounts 
of DI genome (P5) showed a highly decreased IFN-β-level measured 24 h post infection (hpi) 
by qRT-PCR (Figure 5 C). This was in line with the decreased immunostimulatory effect of 
the total RNA isolated at this time point from the infected cells and used for re-transfection 
of uninfected 1205Lu cells. In this assay, that measures the amount of immunostimulatory 
RNA in a cell at a certain time point, the IP-10 amount in the supernatant 24 h post 
transfection was strongly decreased when the RNA was isolated from cells infected with the 
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P5 stock compared to cells infected with the P0 stock (Figure 5 D). These results are in 
accordance with the hypothesis that DI genomes are the main trigger of the interferon 
response after VSV infection. 
 
 
Figure 5: The DI genome of VSV has a major impact on the immune response. The generation 
of P5 was performed by serial dilution of the original VSV stock P0 on BHK cells. (A) HEK293T 
cells grown in a 24-well plate were infected with either VSV stock P0 or P5 (MOI=1). 24 h later 
the cells were lysed and RNA was isolated. The RNA was analyzed by qRT-PCR for (B) DI 
genome and (C) IFN-β mRNA level normalized to HPRT. (D) The isolated RNA was further used 
for transfection of 1205Lu cells in a 96-well plate and the amount of IP-10 in the supernatant 
was measured by ELISA 24 h post stimulation. Data are shown as mean ± SEM (n=3).  
 
Since the previous results could show binding of the DI genome to RIG-I and suggested a 
strong effect on interferon induction, it was of further interest to determine the specific size 
the immunostimulatory RNA has and if there are differences between the viral stocks P0 and 
P5.  
To address this question, the RNA of HEK293T cells infected with either P0 or P5 was isolated 
and separated on an agarose gel. To separate the RNA according to size, the gel was size-
dependently cut into ten fractions (Figure 6 A). The RNA of each fraction was re-isolated and 
used for re-transfection into 1205 Lu cells. The amount of IP-10 was measured 24 h post 
transfection by ELISA, representing the immunostimulatory effect of the transfected RNA 
(Figure 6 B, C).  
RNAs of the fractions with long RNA molecules (>10 – 4 kb) showed induction of IP-10 for 
both viral stocks P0 and P5 although the total amount of IP-10 differed highly between these 
stocks. The overall strongest IP-10 induction was observed in the fraction containing RNA 
molecules of 4 – 6 kb for the P0 stock (Figure 6 B). This fits to the size of the detected DI 
genome (4719 bp) and as expected, this immunostimulatory effect was absent in the stock 
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with low level of DI genomes (P5) (Figure 6 C). To show that the RNA fragmentation 
according to size worked, cDNA of each fraction of P0 was generated and analyzed by qRT-
PCR for the amount of DI genomes (Figure 6 D) and the N protein of VSV (Figure 6 E). The 
Ct-values were normalized to the initial RNA volume. Indeed, most of the DI genome 
(4719 bp) as well as RNA encoding the N protein (1326 bp) were detected in the expected 
fraction.  
Together, these data confirmed that the DI genome is the main trigger of the immune 
response and indicate that the full-length genome (>10 kb) is also able to induce an immune 
response.   
 
 
Figure 6: Size dependent profile of immunostimulatory RNA confirms the role of the DI 
genome. (A) RNA of HEK293T cells grown on 10 cm² dish and infected with VSV stock P0 or 
P5 for 24 h was isolated and separated on an agarose gel. The gel was size-dependently cut into 
ten fractions and RNA of each fraction was re-isolated. (B, C) 10 µl of each fraction was 
transfected into 1205Lu cells in a 96-well plate and the IP-10 concentration in the supernatant 
was measured 24 h after transfection by ELISA. Data are shown as mean ± SEM (n=3). The 
isolated RNA of each fraction of P0 was further transcribed into cDNA and the amount of (D) DI 
genome and (E) N protein was quantified by qRT-PCR and normalized to the initial RNA volume. 
The data show one representative experiment.  
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3.1.3 The defective interfering genome and Leader/N sequences of VSV are     
         enriched after RIG-I immunoprecipitation 
To validate the results of the RNA-fragmentation and the indicated role of the full-length 
genome as RIG-I ligand in the absence of DI genomes, the flag-RIG-I IP already done for the 
virus P0 by Andreas Linder was repeated for the stock P5 to compare the enriched genomic 
sequences by qRT-PCR.  
The enrichment of each genomic part was calculated as ratio of flag-RIG-I expressing cells to 
the negative control (Flip-In) that do not express flag-RIG-I. Both viral stocks showed a 
comparable enrichment of the Leader/N sequences. That could either represent a so-called 
Leader/N readthrough transcript or the full-length genome. As expected, the enrichment of 
the DI genome was gone. The same was true for the L, L/trailer and trailer sequences, 
indicating that most of the enrichment in these sequences resulted from the DI genome 
(Figure 7).  
In summary, the data could clearly show that in our standard stocks the DI genome is the 
main trigger of RIG-I. In the absence of DI genomes other VSV sequences, most likely 
Leader/N containing sequences such as read-throughs or the full-length genome, seem to 
bind to RIG-I but induce a much weaker interferon response.  
 
 
Figure 7: The DI genome and Leader/N sequences of VSV are enriched after RIG-I 
immunoprecipitation. HEK293T cells grown in 175 cm² flasks either overexpressing flag-RIG-
I or not (Flip-In) were infected with either VSV stock (A) P0 or (B) P5 with an MOI = 1. 24 h later 
the cells were lysed and a flag-IP was performed. The co-immunoprecipitated RNA was isolated 
and analyzed for the indicated genomic segments by qRT-PCR. The relative enrichment 
represents the ratio of flag-RIG-I expressing cells to the negative control. Data are shown as 
mean ± SEM (n=3 (A) and n=2 (B)).  
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3.2 Identification of potential MAVS interaction partners by APEX- 
      mediated proximity-based labeling 
3.2.1 MAVS-APEX fusion proteins display MAVS and APEX activity  
The first requirement to use the method of proximity-based APEX-labeling for the analysis of 
the MAVS-associated proteome, was a fusion protein that combines the functions of MAVS 
and APEX. Since the fusion site of the proteins is critical to keep both protein functions intact, 
different sites of MAVS were chosen and tested for the integration of APEX (Figure 8 A). As 
a negative control, only the transmembrane (TM) domain of MAVS was fused to APEX. This 
construct should have the same localization in the mitochondrial membrane as MAVS and 
the enzymatic function of APEX but without the MAVS domains that integrate the molecule 
into the RIG-I signaling pathway. For every construct, besides APEXN-MAVS, a second variant 
was generated that was flag-tagged at the N-terminus of APEX, thus allowing the detection 
of APEX. Furthermore, for the constructs, that contained APEX fused to the TM domain 
(APEX-TM and APEX510-MAVS) a flexible linker (N`GGAAS`C) was introduced to allow proper 
protein folding. 
To begin with, the constructs were tested for expression of the fusion protein. For that, 1205 
Lu cells were used in which endogenous MAVS was knocked out using the CRISPR/Cas9 
system (MAVS-KO). Each construct was transfected and analyzed by Western blot with a 
MAVS-specific antibody (Figure 8 B). As expected, MAVS expression was missing in the 
APEX-TM construct and all other constructs showed a MAVS specific band with an apparent 
size of approximately 110 kDa. Two of the constructs (APEXNMAVS, APEX84MAVS) showed 
an additional band, indicating that a part of the protein got cleaved, which could be due to 
improper folding. This is in line with the immunofluorescence staining that was done to 
control for correct localization of the constructs. Whereas the localization for the three 
constructs APEX264MAVS, APEX510MAVS and APEX-TM is restricted to mitochondria, the 
constructs showing additional bands in the Western blot also show cytoplasmic background 
staining (APEXNMAVS, APEX84MAVS) (Figure 8 C).  
After demonstrating the correct expression and localization for three out of five constructs, 
they were analyzed for intact MAVS signaling. Again, the 1205Lu MAVS-KO cells were used 
to transfect the constructs. For induction of MAVS signaling 3p-RNA was used as a stimulus. 
3p-RNA acts as a specific ligand for RIG-I, thus leading to activation of MAVS and its 
downstream signaling cascades. The measurement of IP-10 in the supernatant of cells 24h 
after 3p-RNA stimulation by ELISA was used as read-out for intact MAVS signaling. The two 
MAVS-APEX fusion constructs that possessed the expected expression pattern and 
localization showed an IP-10 production comparable with transfected wt-MAVS and as 
expected, APEX-TM was impaired for signaling (Figure 8 D). 
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Figure 8: Different MAVS-APEX fusion proteins show intact MAVS localization and 
signaling. (A) Different MAVS-APEX fusion proteins were constructed by fusion of APEX to 
different sites of MAVS. 1205Lu MAVS knockout cells were transfected with 500 ng/ml of each 
construct for 24 h. (B) The size and expression pattern were analyzed by Western blot and (C) 
the localization by immunofluorescence and co-staining of mitochondria with Mitotracker red 
and MAVS or flag to detect the APEX-TM construct. (D) The function of MAVS signaling upon 
RLR activation was analyzed after stimulation with 500 ng/ml 3p-RNA via measurement of 
IP-10 in the supernatant by ELISA 24 h post stimulation. Data are shown as mean ± SEM (n=2 
to 3; except APEX264MAVS and APEX-TM n=1). 
 
In the next step, the functionality of APEX was analyzed. Again, 1205 Lu MAVS-KO cells were 
used for transfection of the constructs and 24 h post transfection the reaction of APEX was 
induced as described in 2.2.9. 
The pattern and strength of biotinylation was analyzed by Western blot and 
immunofluorescence. As a positive control a plasmid was transfected that expresses APEX 
fused to a mitochondrial target sequence leading to localization into the mitochondrial matrix 
(mito-APEX). For this construct it was shown that biotinylation is highly restricted to the 
mitochondria (128). The expression pattern detected by Western blot with Streptavidin-HRP 
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is the same for all fusion constructs but differs from the pattern resulting from mito-APEX, 
indicating that they biotinylate a different set of proteins. Except for the APEX84MAVS 
construct, all other fusion proteins are functional for APEX and show a comparable amount 
of biotinylation (Figure 9 A). The actual site of biotinylation within the cell was further 
analyzed by immunofluorescence using Streptavidin-FITC for detection of biotin. Herein, only 
these constructs were tested that had shown an intact MAVS signaling. Additionally, APEX-
NES that expresses APEX unspecifically in the cytoplasm was used as a negative control. As 
expected, this construct biotinylates all cytoplasmic proteins, whereas the biotinylation 
induced by the mito-APEX construct is highly restricted to the mitochondria. All generated 
fusion proteins showed an enhanced biotinylation at the site of mitochondria with slight 
background biotinylation of cytoplasmic proteins.   
In summary, two MAVS-APEX fusion constructs - APEX264MAVS and APEX510MAVS - as well 
as the negative control APEX-TM showed the expected properties concerning the activity of 
MAVS and APEX as well as the specificity of APEX no matter whether flag-tagged or 
untagged APEX was used. 
 
 
3 Results 48 
 
 
Figure 9: Different MAVS-APEX fusion proteins show specific APEX activity. (A) APEX 
activation is induced by addition of biotin phenol for 30 min and H2O2 for 1 min to the cell culture 
medium and is supposed to biotinylate all proteins in close proximity of the APEX-MAVS fusion 
protein. 1205 Lu MAVS-KO cells were transfected with 500 ng/ml of the indicated construct for 
24 h. After activation of APEX for one minute (B) the pattern and strength of biotinylation was 
checked by Western blot with Streptavidin-HRP. (C) The localization of the subset of biotinylated 
proteins was analyzed by immunofluorescence using Streptavidin-FITC and MAVS-specific 
antibody or flag-specific antibody for detection of the APEX-TM construct. 
 
3.2.2 Generation of a reproducible system by stable transduction of the fusion  
         proteins  
After confirming their intact functionalities, the constructs APEX510MAVS and APEX-TM 
were used for further experiments. Since APEX is fused to the same site of the TM domain of 
MAVS in both constructs, these two constructs are suitable to distinguish MAVS-specific 
labeling from labeling due to localization in the outer mitochondrial membrane. Both 
constructs were cloned in a retroviral vector system that additionally encodes for a puromycin 
resistance. The construct of APEX510MAVS was transduced for stable integration into the 
genome of 1205 Lu MAVS-KO cells and the APEX-TM construct into the wt background. 
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Hence, both cell lines are able to induce MAVS signaling. After transduction the cells were 
selected with puromycin for integration-positive cells.  
Whereas for APEX-TM all transduced cells showed flag expression and the expected 
biotinylation pattern (Figure 10 D), for APEX510MAVS only a few transduced cells showed 
MAVS expression and biotinylation. These cells were further sub-cultured into single cell 
clones and analyzed for MAVS expression (Figure 10 A) and signaling capacity measured by 
IP-10 in the cells supernatant 24 h after 3p-RNA stimulation (Figure 10 B). For further 
experiments clone 7 was picked showing MAVS expression and IP-10 induction comparable 
to wt cells. Furthermore, this clone was also functional for APEX, although the level of 
biotinylation differed between the cells in this population (Figure 10 C).  
These results demonstrate that both cell lines are suitable tools for the envisioned pull-down 
experiments. Herein, the APEX-TM transduced cells will serve as negative control. Since they 
have endogenous MAVS, they are able to signal, but the biotinylation will not be MAVS-
associated. It is the whole outer mitochondrial membrane, that is expected to be biotinylated 
in this cell line. 
 
 
Figure 10: Generation of a reproducible system by stable transduction of the fusion 
proteins. The fusion construct APEX510MAVS or APEX-TM were transduced into 1205 Lu 
MAVS-KO or 1205 Lu wt cells, respectively. After transduction of APEX510MAVS single cell 
clones were analyzed for (A) expression level of MAVS and (B) IP-10 in the supernatant was 
measured by ELISA 24 h after 3p-RNA (500 ng/ml) stimulation (n=3). After activation of APEX 
reaction by addition of biotin phenol for 30 min and H2O2 for 1 min the reaction was stopped. 
The expression pattern of each construct was analyzed with either (C) MAVS-specific 
antibodies and co-staining with Mitotracker or (D) flag-specific antibodies and co-staining with 
MAVS-specific antibody. Biotinylated proteins were stained with Streptavidin-FITC. 
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3.2.3 APEX-MAVS specifically labels MAVS interaction partners upon RLR  
activation 
Since MAVS signaling is a highly dynamic process, it is of great importance to choose the 
right time point after signal activation to look for specific interaction partners.  
In preliminary pull-down experiments, cells were stimulated by transfection of 500 ng/ml 3p-
RNA and the APEX-mediated biotinylation was induced at different time points after 
stimulation. After stopping the reaction, the cells were lysed, and biotinylated proteins were 
pulled down with magnetic streptavidin beads. Bound proteins were eluted from the beads 
by heating, separated by Western blot and analyzed for RIG-I, TBK1 and TRAF3 that are well 
described interaction partners of MAVS (Figure 11). TBK1 and TRAF3 showed a clear 
enrichment after 60 min of stimulation whereas RIG-I was already detected in the 
unstimulated condition and did not get changed over time. Interestingly, the bait protein 
MAVS got decreased after stimulation. The house keeping protein GAPDH used as loading 
control is only hardly detectable after pull-down and did not get enriched after stimulation. 
In contrast, the control cell line APEX-TM wt showed no enrichment of any analyzed protein 
after 3p-RNA stimulation.  
On the one hand that proved that MAVS interaction partners are detectable by APEX-MAVS 
(TBK1 and TRAF3). On the other hand, this indicated that APEX acts highly specific since it 
showed increased biotinylation of MAVS interaction partners after 3p-RNA stimulation only 
for the APEX-MAVS fusion protein but not for mitochondria localized APEX (APEX-TM). 
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Figure 11: APEX-MAVS specifically biotinylates MAVS interaction partners after RLR 
signaling activation. An APEX510MAVS expressing but wt-MAVS deleted cell line or APEX-
TM expressing wt 1205 Lu cells were stimulated with 500 ng/ml of 3p-RNA. At indicated time 
points after stimulation the APEX reaction was induced or cells were left untreated (K-). 
Biotinylated proteins were pulled down with streptavidin beads and analyzed by Western blot 
for known MAVS interaction partners. One representative blot out of two independent 
experiments is shown.  
 
Interestingly, the immunofluorescence staining of biotinylated proteins after 3p-RNA 
stimulation showed a specific dotted pattern that is also only detectable with the APEX-MAVS 
fusion protein but not in APEX-TM control condition. Since the Western blot showed that the 
biotinylated proteins are indeed MAVS interaction partners, the immunofluorescence 
staining indicated that the dotted pattern reflects MAVS signaling platforms that cannot be 
detected by staining MAVS (Figure 12). Thus, this method could be used further to 
specifically visualize and follow the activated MAVS signaling complexes.  
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Figure 12: APEX-MAVS fusion protein induces a specific biotinylation pattern after RLR 
signaling activation. An APEX510MAVS expressing but wt-MAVS deleted cell line or APEX-
TM expressing wt 1205 Lu cells were stimulated with 500 ng/ml of 3p-RNA for 1h or left 
untreated. The APEX reaction was induced, stopped after 1 min and the cells were fixed and 
stained with MAVS-specific antibodies and streptavidin. Mitochondria were stained with 
Mitotracker red. One representative experiment out of three (APEX510MAVS) or two (APEX-
TM wt) is shown. 
 
To further analyze, if this dotted pattern reflects MAVS oligomers and how they behave over 
time, the biotinylation pattern in APEX510MAVS cells was followed over time after 3p-RNA 
stimulation and was co-stained with the MAVS-interacting protein TBK1 (Figure 13).  
Indeed, especially 1h after 3p-RNA treatment there was a strong colocalization of biotin and 
TBK1 in a dotted pattern, supporting the data of the streptavidin pull-down. Up to 4 h after 
3p-RNA treatment the dotted pattern stayed stable, whereas the co-localization with TBK1 
decreased over time.  
On the one hand, that further supports the interpretation that the biotinylated dots reflect 
MAVS oligomers that serve as a trigger for downstream signaling activation. On the other 
hand, it demonstrates that this method is suitable for kinetic studies of the signaling progress.   
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Figure 13: MAVS interaction partner TBK1 colocalizes with biotin at certain time points 
after RLR activation in an APEX510MAVS expressing but wt-MAVS deleted cell line. The cells 
were stimulated for the indicated time points with 500 ng/ml of 3p-RNA. Subsequently the APEX 
reaction was induced and stopped after 1 min with quencher solution. The cells were fixed and 
stained for TBK1 and biotin. One representative experiment out of two is shown.   
 
3.2.4 Mass spectrometry reveals new potential MAVS interaction partners 
As the preliminary pull-down experiment showed, 60 min after stimulation MAVS interaction 
partners were clearly detectable. Because the early interactors of MAVS, that are necessary 
for induction of downstream signaling are of high interest, additionally the time point 15 min 
was chosen and compared to the unstimulated situation in the same cell line.  
The streptavidin pull-down was performed in biological triplicates and the samples were 
further processed for liquid chromatography/ mass spectrometry (LC/MS) analysis in the 
group of Prof. Axel Imhof (Biomedical center, Munich). Each sample was measured in 
technical duplicates. The data analysis was performed with the software Perseus and done in 
cooperation with Prof. Axel Imhof. 
First, the data sets were checked by quality control measures. For that, the overall number of 
detected proteins were compared, showing that in every sample of the respective cell line 
nearly the same amount of proteins was detected. Importantly, most of the detected proteins 
per condition were present in all replicates (Figure 14 A, B).   
To analyze the differences between all samples of each cell line, a principal component 
analysis (PCA) was performed. The PCA is a method used to explain the variance of complex 
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data sets by reducing a big set of variables to smaller sets, the so-called principal factors. In 
fact, the more the samples cluster the more identical they are. For APEX510MAVS this 
revealed that for component 1 all of the replicates cluster together and for component 2 the 
condition 60 min is different from the other conditions (Figure 14 C). For APEX-TM there 
were no clear variances between the conditions but more between the replicates (Figure 
14 D). This indicated, that only the set of detected proteins after 60 min in APEX510MAVS was 
different compared to 0 min or 15 min, awhile the other conditions did not differ. All in all, 
there was no outlier detected and the amount of proteins were comparable. Thus, the quality 
analyzes confirmed a valid data set the could be used for further analyzes. 
 
 
Figure 14: Evaluation of mass spectrometric data by principal component analysis shows a 
valid data set. The streptavidin pull-down after biotinylation of proteins by the APEX reaction 
of each condition were prepared in three biological replicates and measured in technical 
duplicates via LC-MS. The data sets were analyzed with the software Perseus for (A, B) the 
proteins identified in all replicates per condition and (C, D) by principal component analysis 
showing the clustering of all samples per cell line. Each symbol type reflects one replicate and 
each color one condition. 
 
The most interesting question was, if there are any significant changes in protein abundance 
after RLR activation compared to the unstimulated condition. To determine the amount of 
protein in each sample the label-free quantification (LFQ) method was used. For identification 
of changes in LFQ intensities between two conditions a volcano plot was performed. In this 
analysis the difference in LFQ intensity for each detected protein is plotted together with the 
corresponding p-value. Every protein that is plotted outside the marked borderlines has 
significantly different LFQ intensities between the compared conditions.  
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Whereas the APEX510MAVS cells stimulated for 15 min showed no significantly altered 
protein (Figure 15 A), after 60 min 31 proteins were found to be significantly enriched (Figure 
15 B, Table 2 (appendix)). In contrast, the control cell line APEX-TM showed no significant 
change in protein abundancy after 60 min of stimulation (Figure 15 C).  
 
 
Figure 15: 31 significantly altered proteins were detected after 60 min of RLR activation in 
APEX510MAVS cells. Label-free quantification (LFQ) determining the relative protein amount 
was used for calculating alteration in protein quantities. Significantly altered proteins were 
identified using the software Perseus and are depicted in a volcano plot after (A) 15 min or (B) 
60 min of 3p-RNA stimulation compared to unstimulated for APEX510MAVS or after (C) 60 min 
for APEX-TM wt.  
 
The identified candidate proteins were further analyzed using the online tool string-db.org 
that searches for functional protein interaction networks. This revealed a subset of 14 
proteins that cluster together with MAVS showing links that are derived from curated 
databases (Figure 16 A).  
This is also reflected by the pathway analysis the string-db.org online tool provides. Here, the 
most significantly enriched biological processes in which the candidate proteins are involved 
were found to deal with innate immune signaling, such as NFκB and PRR signaling. 
Reassuringly, the most significant KEGG pathway coming up is the RLR signaling pathway 
(Figure 16 B).  
All in all, these analyzes convincingly showed that almost half of the identified proteins are 
known MAVS interaction partners. Since these proteins were not detectable with the control 
3 Results 56 
 
cell line APEX-TM, the method works highly specific for MAVS and not only for a subcellular 
compartment, like the outer mitochondrial membrane.  
All the other detected proteins that have no connection to this known MAVS network share 
no other common KEGG pathway. The main common feature is their localization at the 
mitochondria (11 out of 17 proteins). All these newly identified proteins, for which a 
connection to the RLR signaling is not yet known are highly interesting candidates to be 
further analyzed for their function in MAVS-dependent signaling.  
 
 
Figure 16: Identified proteins contain numerous known MAVS interaction partners but also 
reveal novel candidates. All significantly altered proteins together with MAVS were analyzed 
using the online tool https://string-db.org for functional protein association networks. (A) The 
links between the proteins are derived from curated databases. (B) The most significant 
biological processes and KEGG pathways the candidate proteins are involved in are listed. 
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3.2.5 Cell lines deficient in the newly identified potential MAVS-interaction   
           proteins have a phenotype for antiviral signaling 
As the proximity labeling experiment produced a list of 17 candidate proteins that are not 
(directly) described in MAVS-dependent signaling yet, different criteria were used to select 
the most interesting candidates within this list for further characterization. One important 
criterium was its described function, i.e. in which pathways it is involved, what are its 
interacting proteins and how does it act on the molecular level. Further the sub-cellular 
localization was considered (cytoplasm, inner or outer mitochondrial membrane, 
extracellular) as well as the significance level depicted in the volcano plot (Figure 15 B). 
Finally, a set of RNA sequencing data generated in our group was analyzed for the candidate 
proteins. Here, in 1205 Lu cells the total mRNA levels of unstimulated cells were compared 
to cells treated with 3p-RNA for 6h. The data were screened for any significant changes for 
the candidate proteins.  
Based on these criteria, eight proteins were selected to be screened for their function in 
MAVS signaling, namely UBASH3B, CCDC50, N4BP1, Sorcin (SRI), WIPI1, CHCHD3, 
Tenascin C (TNC C) and Optineurin (OPTN). Although OPTN is one of the proteins included 
in the protein network derived from the string database, its function in RLR signaling is still 
not clearly described. Thus, it works on the one hand as a positive control as there was the 
expectation to see an effect on MAVS signaling and on the other hand it is still of interest to 
reveal its mode of action in MAVS signaling. 
To see if the proteins of interest have any effect on RLR signaling, knockout (KO) cells were 
generated using the CRISPR/Cas 9 gene editing system. Single cell clones (SCC) were 
considered as complete KO, if both alleles showed an out-of-frame mutation thus, causing an 
early stop codon and loss of the protein. For each protein two to five SCC were generated, 
with the exception of CHCHD3. Here, for all the analyzed SCC more than two alleles have 
been detected and at least one was still wildtype, indicating that a complete KO of this protein 
is lethal. 
In a first functional screening approach, four different gene KOs (UBASH3B, OPTN, SRI, 
CCDC50) were analyzed. All SCC have been tested for their immune response upon 
stimulation with the MAVS-specific ligand 3p-RNA and a MAVS-independent PRR ligand pIC. 
By adding pIC onto the cells without transfection, it activates the TLR3 pathway. This was 
used as a control, because it activates a similar immune response via IRF3 as well as the 
NFκB pathway but is independent of MAVS.  
After stimulating the cells with the respective ligand for 6 h the supernatant was taken and 
the concentration of the cytokine IP-10 was measured via ELISA (Figure 17). 
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Figure 17: Analysis of the immune response in different gene knockouts. For each gene 2- 5 
different single cell clones (grey) and a pool containing same amounts of each single cell clone 
(patterned) have been tested in comparison to 1205 Lu wt cells. The cells were grown in 96-well 
plate, stimulated with (A) 3p-RNA (500 ng/ml) or (B) untransfected pIC (5 µg/ml) for 6 h and IP-
10 in the supernatant was measured by ELISA. Data are shown as mean ± SEM from 2-5 
independent experiments.   
 
All KO cells showed an increased IP-10 release compared to the wt cells when stimulated 
with the RIG-I-specific ligand 3p-RNA. Upon stimulation with untransfected (ut) pIC only the 
CCDC50- and OPTN-KO cells showed a clear increase in IP-10 release that is consistent 
throughout the different SCC, whereas the UBASH3B-KO cells had IP-10 levels like wt cells. 
The SRI-KO SCC behaved differently with 2 clones showing an increase and 3 clones show 
lower or equal IP-10 amounts, but the mixed population showed a much higher IP-10 level 
than the wt cells.  
This suggests, that all the proteins have a negative influence on the antiviral signaling, no 
matter if the signaling is MAVS-dependent or not. Only UBASH3B indicates an RLR-MAVS-
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specific phenotype, since the cytokine release was only increased upon 3p-RNA stimulation 
but not with utpIC.  
3.2.6 UBASH3B shows a negative regulatory function on RLR signaling 
Considering this initial screening together with the set criteria, the decision was taken to look 
deeper into the role of UBASH3B. The considerations thereby were, that the ELISA data 
hinted towards an RLR-MAVS-specific phenotype, that it was the protein showing the most 
significant change in the volcano plot besides the known MAVS interactors and that its mRNA 
level was found to be significantly downregulated upon RLR-MAVS signaling activation. 
Furthermore, UBASH3B is described to modify different proteins post-translationally by 
dephosphorylation of ubiquitinated proteins. Post-translational modification is known to be 
an important feature that regulates MAVS activity.  
To have a valid set of UBASH3B-KO cells, another round of CRISPR/Cas9 editing was 
performed. To exclude sgRNA-specific off-target effects, two sgRNAs targeting different sites 
of UBASH3B gene (sg1 and sg2) were used and SCC were screened by deep sequencing in 
the group of Prof. Veit Hornung (Gene center, Munich). The sequences were analyzed with 
the online tool outknocker.org giving the number of reads per sequencing as well as the type 
and amount of inserted mutation. Those clones having a homozygous or compound 
heterozygous out-of-frame mutations were further analyzed on Western blot for UBASH3B 
and Cas9 expression (Figure 18). Although the cells were only transiently transfected with 
the Cas9-encoding plasmid, some cells stably integrated its cDNA into their genome. 
Integration and constant expression of Cas9 and the sgRNA could later hinder the 
reconstitution of UBASH3B and could cause off-target effects. To avoid this, only SCC were 
chosen that were negative for UBASH3B as well as for Cas9. For each sgRNA five SCC that 
are marked in squares (Figure 18 A, B) and highlighted in bold (Figure 18 C) were used for 
further analysis.  
As a control for the CRISPR/Cas9 treatment a cell pool was used that was transfected with a 
scrambled sgRNA that do not target any specific DNA site. Instead of single cell clones, all 
transfected cells were selected on puromycin and the whole remaining cell pool was used. 
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Figure 18: Generation of multiple UBASH3B-knockout cells in 1205 Lu cells. 1205 Lu cells 
were transfected with eSpCas9 plasmids either encoding sg1 or sg2. After puromycin selection 
and limiting dilution single cell clones were expanded and the CRISPR target site was (A, B) 
analyzed by deep sequencing and the online tool outknocker.org. (C) Clones showing homo- or 
heterozygous out-of-frame indels were further analyzed by Western blot for UBASH3B and Cas9. 
The clones highlighted in bold lacking UBASH3B and Cas9 were chosen for further experiments.    
 
To confirm the results from the first two UBASH3B-KO SCC the new cell lines were also tested 
for their cytokine release upon 3p-RNA treatment. Again, the supernatant was taken 6 h after 
3p-RNA stimulation, IP-10 and additionally Il-6 was measured. Whereas the promoter of IP-
10 is driven by IRF3 and NFkB activation, the IL-6 production does not depend on IRF3 
activation. Each SCC was either tested separately or in an equally mixed cell population of 
sg1 or sg2 derived cells or all SCC together (sg1+sg2). These pooled cells should minimize 
possible off-target effects in the SCC. Although each SCC produced different amounts of IP-
10 and IL-6, most of the SCC produced more of the cytokine compared to wt or scrambled 
cells. The pool of KO clones generated with both sgRNAs induced more of each cytokine and 
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the effect was somewhat stronger for the KO cells generated with sg1 (Figure 19 A, B). This 
was in line with qRT-PCR data showing that both KO clone pools had increased mRNA levels 
for IP-10, IFN-β, IL-6 and IL-1β compared to wt cells and cells treated with scrambled sgRNA. 
For IFN-β, there was already significantly more mRNA in the KO cells compared to the 
controls after 2 h of 3p-RNA treatment (Figure 19 D). For all the other cytokines the biggest 
difference was measured after 6 h, and after 12 h the difference in mRNA levels for IP-10 and 
IL-1ß were still increasing (Figure 19 C, F), whereas for IFN-ß and Il-6 the levels equal again 
(Figure 19 D, E).  
 
Figure 19: UBASH3B-knockout shows a phenotype on cytokine expression after RLR 
signaling activation. The UBASH3B-KO SCC generated with sg1 (5) or sg2 (5) were either 
separately tested or used as a mixed cell population of each sgRNA (sg1 mix; sg2 mix) or as 
mixed population of every SCC (sg1+sg2). As control 1205 Lu wt cells and a batch of scrambled 
sgRNA treated cells were used. The cells were plated in 96-well plate, stimulated for 6 h and the 
amount of (A) IP-10 and (B) IL-6 was measured in the cell’s supernatant via ELISA. The dotted 
line shows the highest standard level of the assay. (C-F) For qRT-PCR each cell population (wt, 
scrambled, sg1 mix and sg2 mix) grown in 24-well plate were stimulated with 3p-RNA 
(500 ng/ml) for indicated time points. The RNA was isolated, transcribed into cDNA and 
analyzed for the mRNA level of the indicated cytokines via qRT-PCR. Subsequently, the data of 
UBASH3B-KO cells (sg1 mix, sg2 mix) and control cells (wt, scrambled) were pooled. Data are 
shown as mean ± SEM from 3 (A-C) or 4 (D-F) independent experiments.   
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To have a closer look on the upstream signaling events prior to induction of the cytokines, 
the activation of MAVS itself and its downstream molecules were analyzed. For this, the 
mixed population of SCC of sg1 or sg2 were compared to the control wt or scrambled cells at 
different time points after 3p-RNA stimulation.  
Upon activation, MAVS forms RIPA-insoluble oligomers causing a shift from the soluble into 
the insoluble fraction. Thus, activated and thereby aggregated MAVS can be found as a smear 
on Western blots in the pellet fraction of cell lysates after centrifugation. In both UBASH3B-
KO cell pools (sg1 and sg2) MAVS oligomers were detected earlier and stronger upon 3p-
RNA treatment (Figure 20 A, E) compared to UBASH3B-containing cells. The same was true 
for the analyzed downstream molecules. The activation of TBK1 was determined, since it 
directly interacts with MAVS and is crucial for downstream activation of the IRF3 pathway 
and is also described to be involved in the activation of the NFκB signaling branch. The 
phosphorylation reflecting its activation was significantly higher in UBASH3B-deficient cells 
compared to wt cells after 3 and 6 h of 3p-RNA treatment (Figure 20 A, B). The analysis of 
further downstream molecules indicated that both main signaling branches were affected, 
because IRF3 as well as IκBα (NFκB-activation) showed stronger phosphorylation in the KO 
cells after signaling activation (Figure 20 C, D). For all these proteins the differences in its 
activation was only seen at early time points up to 6 h, whereas there was no difference 
anymore after 9 h. Interestingly, the protein level of UBASH3B decreased in the wt cells upon 
stimulation with 3p-RNA. This finding is in line with the mentioned RNA sequencing data of 
1205 Lu cells done in collaboration with Dr. Lars König showing a significant decrease on 
mRNA level of UBASH3B upon 3p-RNA stimulation.  
In summary, these data support the initial finding that UBASH3B-KO in 1205 Lu cells cause 
an enhanced immune response upon 3p-RNA stimulation measured by cytokine production. 
The kinetics further indicate, that the level of UBASH3B is especially important at the onset 
of signaling, since the early time points after stimulation were affected the most. 
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Figure 20: UBASH3B-knockout cells show an earlier and stronger activation of MAVS and 
its downstream molecules upon stimulation with 3p-RNA. 1205 Lu wt or scrambled cells as 
well as a mixed population of five SCC of either sg1 (sg1 SSC mix) or sg2 (sg2 SSC mix) were 
stimulated with 3p-RNA (500 ng/ml) for indicated time points. (A) The cells were lysed and the 
lysate and insoluble pellet were analyzed by Western blot for the indicated proteins. (B-E) The 
protein levels were quantified by calculating the intensities of the bands normalized to the total 
protein load with the software Image Lab. The data for sg1 and sg2 SCC mix or for control cells 
(wt and scrambled) were pooled and are shown as mean ± SEM from 3 independent 
experiments.   
 
Working with SCC, especially derived from a cancer cell line like the 1205 Lu, is prone to 
clonal variation in addition to the targeted gene deletion. We tried to control for those off-
target effects by using different sgRNAs. But there is still the possibility of random mutations 
that arise from multiple division of a single cell in the process of the limiting dilution process. 
To circumvent this, batches of UBASH3B KO cells were generated with both sgRNAs. Here, 
the transfected cells were only selected with Puromycin and all surviving cells were cultivated 
as a batch. As a control, cells underwent the same procedure but were treated with scrambled 
sgRNA. Again, the cells were stimulated with 3p-RNA and tested for their IP-10 release via 
ELISA and the activation of MAVS and downstream molecules by Western blot. Both read-
outs confirmed the findings from the SCC by showing a higher IP-10 production in both 
UBASH3B-KO batches compared to the scrambled cells (Figure 21 A) as well as a stronger 
activation of MAVS and the downstream molecules TBK1, IRF3 and IκBα (Figure 21 B). The 
Western blot for UBASH3B further showed that both KO batches generated with sg1 or sg2 
had a high knockout efficiency. There were still some cells expressing UBASH3B which could 
explain the smaller differences between KO cells and cells treated with scrambled sgRNA in 
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the IP-10 production as well as in the activation of the signaling molecules compared to SCC 
being complete KO.  
 
 
Figure 21: Batches of UBASH3B-knockout cells show the same phenotype as single cell 
UBASH3B knockout clones. 1205 Lu cells were treated with either UBASH3B-specific sgRNAs 
sg1 or sg2 or scrambled control sgRNA and cultivated as a cell batch. (A) The cells were 
stimulated with 3p-RNA (500 ng/ml) for 6 h and the amount of IP-10 was measured in the cell’s 
supernatant via ELISA. Data are shown as mean ± SEM from 3 independent experiments. (B) 
The cells were lysed after indicated time points of 3p-RNA stimulation and analyzed for the 
indicated proteins by Western blot. GAPDH was used as a loading control. Shown is one 
representative Western blot out of 3 independent experiments.  
 
To see if the identified phenotype for UBASH3B-KO is only specific for 1205 Lu cells, 
additionally human fibroblasts were tested. These cells have some major differences to 1205 
Lu cells, since they are derived from healthy donors and do not have the genetic instability 
of cancer cells and are therefore biallelic which makes it easier to distinguish between single 
or multiple cell clones. These primary cells were immortalized by transduction of the human 
telomerase reverse transcriptase (hTERT) that avoids the reduction of the telomeres.  
These immortalized fibroblasts were treated with the UBASH3B-specific sgRNA sg1, 
expanded as SCC and analyzed by deep sequencing. Four SCC that were proven to be 
complete KO via DNA sequencing as well as on protein level were taken for analyzes of their 
phenotype in RLR signaling and were compared to wt cells.  
Similar to the 1205 Lu cells, UBASH3B deficiency in these fibroblasts lead to a higher 
induction of IFN-β and IP-10 at the early time points (Figure 22 A, B). IL-1β was significantly 
increased after 6 h (Figure 22 D) and although the differences for IL-6 were not significant, 
the KO cells tended to induce more IL-6 at all time points (Figure 22 C).  
In line with the 1205 Lu cells, the UBASH3B-KO fibroblasts also showed a stronger and earlier 
MAVS activation. The same was true for the activation of IκBα (p-IκBα) (Figure 22 E). 
Unfortunately, p-TBK1 and p-IRF3 could not be detected in these cells.   
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All in all, the data of UBASH3B-KO cells provide evidence, that UBASH3B has a negative 
impact on the activation of MAVS and different downstream signaling pathways and is 
especially important at the onset of the signaling cascade. The observation of the same 
phenotype in two different cell lines suggests that the function of UBASH3B in RLR signaling 
is not cell type specific.  
 
 
Figure 22: UBASH3B deficiency in human Fibroblasts has the same phenotype as in 1205 
Lu cells. Four UBASH3B-KO SCC of human fibroblasts were used as equally mixed cell pool and 
compared to wt cells. The cells grown in a 24-well plate were stimulated for the indicated time 
points with 500 ng/ml of 3p-RNA. (A-D) Subsequently, the RNA was isolated, cDNA was 
synthesized and analyzed for expression of the indicated cytokines by qRT-PCR. Data are shown 
as mean ± SEM from 3 independent experiments. (E) The cells were lysed and analyzed for the 
indicated proteins by Western blot. Shown is one representative Western blot out of 3 
independent experiments.  
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3.2.7 Overexpression of UBASH3B has an inhibitory effect on RLR signaling in    
         HEK293T cells but not in 1205 Lu cells 
To further confirm that the phenotype detected in the UBASH3B-KO cells was indeed caused 
by the lack of UBASH3B, this protein was overexpressed.  
Firstly, UBASH3B was transiently overexpressed in 1205 Lu wt cells by transfection of two 
different plasmid concentrations. Although the protein was dose-dependently overexpressed, 
there was no effect on the formation of MAVS oligomers nor on the amount of 
phosphorylation of TBK1, IRF3 or IκBα (Figure 23).  
 
 
Figure 23: Transient Overexpression of UBASH3B in 1205 Lu cells has no effect on MAVS 
signaling. 1205 Lu wt cells were transiently overexpressed with increasing amounts UBASH3B. 
The empty vector pcDNA3 was used to keep the total amount of transfected DNA constant. 24 h 
after transfection the cells were stimulated with 3p-RNA (500 ng/ml) for 6h, the cells were lysed 
and analyzed on Western blot for the indicated proteins. The data show one representative blot 
out of two independent experiments.  
 
1205 Lu cells have a low transfection efficiency and transfection itself can cause artefacts. To 
circumvent these limitations, the 1205 Lu wt cells and one UBASH3B-KO clone was stably 
transduced with a plasmid encoding UBASH3B under the control of a doxycycline-inducible 
promoter (pLVX system; see 2.2.6). The main advantage of this system is, that the same cell 
population can be used and different expression levels of UBASH3B can be induced 
depending on the doxycycline concentration used for induction (Figure 24 A).  
However, the induction of two different UBASH3B level in the wt or in the KO background 
showed no altered activation of MAVS analyzed by oligomer formation on Western blot 
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(Figure 24 B) and no changes in cytokine induction measured by qRT-PCR (Figure 24 C – F), 
which led to the conclusion that the UBASH3B phenotype in 1205 Lu cells cannot be rescued. 
Here, an interesting finding is, that not only endogenous UBASH3B as provided by the RNA 
sequencing data is downregulated upon 3p-RNA treatment but also UBASH3B transcribed 
from an artificially introduced vector system that lacks the endogenous promoter (Figure 24 
G). This indicates that the mRNA level might not be regulated pre- but post-transcriptionally, 
meaning there is some factor induced by RLR signaling that destabilizes UBASH3B mRNA.   
 
 
Figure 24: Stable, inducible overexpression of UBASH3B in 1205 Lu cannot rescue its 
phenotype. 1205 Lu wt or one UBASH3B-KO clone were stably transduced with UBASH3B 
using a doxycycline-inducible system. (A) Different concentrations of doxycycline were used to 
induce UBASH3B expression for 24 h. The cells were stimulated for indicated time points with 
3p-RNA (500 ng/ml) and analyzed (B) via Western blot for MAVS aggregates in the pellet fraction 
or (C-G) mRNA levels of the indicated proteins were measured via qRT-PCR in the UBASH3B-
KO background. Shown is one representative experiment out of two biological replicates.  
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Although an effect of UBASH3B overexpression on MAVS signaling in 1205 Lu cells was not 
detectable, HEK293T cells showed the expected phenotype in luciferase reporter assay.  
Here, either RIG-I, MAVS, MAVS-K7/10R, TBK1 or IRF3-5D – a constitutive active IRF3 
mutant – were overexpressed along with increasing amounts of UBASH3B or its mutant 
variant H391A. This mutation is described to highly decrease the phosphatase activity of 
UBASH3B (141). With overexpression of the respective signaling molecule the signaling 
cascade starts on the level of this molecule. The IFN-β promoter activity showed a dose 
dependent decrease when UBASH3B was overexpressed with RIG-I. This decrease was 
stronger and more significant when UBASH3B was co-expressed with MAVS or its mutant 
K7/10R. This MAVS mutant lacks the ubiquitination site at the lysine residue 7 and 10 and is 
therefore described to be incompetent for degradation (91). Furthermore, the UBASH3B 
mutant H391A showed the same effect as the wt variant, when co-expressed with MAVS. In 
contrast, overexpression of TBK1 or IRF3-5D did not show any UBASH3B-dependent 
regulation.  
Together these results indicate, that UBASH3B targets the RLR signaling on the MAVS level. 
Further, the Ubiquitin-chains linked to lysine residues K7 and K10 do not seem to be the 
binding site of UBASH3B since mutation of the MAVS ubiquitination sites K7/10R that inhibit 
the ubiquitin-mediated degradation of MAVS do not seem to be important for the effect of 
UBASH3B on MAVS signaling. Also, the UBASH3B phosphatase domain does not seem to be 
important to exert the function of UBASH3B on MAVS.  
 
Figure 25: Overexpression of UBASH3B causes a MAVS-dependent downregulation of 
antiviral signaling in HEK293T cells. HEK293T cells grown in 96-well plate were transfected 
with increasing amounts of UBASH3B wt or the phosphatase-dead mutant UBASH3B H3191A 
(0/250/500/1000/1500 ng/ml) together with 250 ng/ml of the indicated signaling protein and 
luciferase reporter plasmid for IFN-β 24 h after transfection, the luciferase activity was measured 
and normalized to the renilla activity. This relative activity was again normalized to the condition 
that lacks UBASH3B overexpression. This condition was used as reference to calculate the 
significance level. The data are shown as mean ± SEM from 4 to 6 independent experiments.   
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To further investigate how UBASH3B mediates its inhibitory effect seen in HEK293T cells, 
MAVS was overexpressed together with increasing amounts of UBASH3B and the pellet 
fraction was analyzed for MAVS oligomers by Western blot. This experiment showed that 
indeed the amount of aggregated - and that implies activated MAVS - is decreased with 
increasing amounts of UBASH3B, whereas the amount of full-length MAVS in the lysate was 
not affected. Interestingly, the smaller transcript of MAVS – miniMAVS – showed a clear 
reduction in the presence of UBASH3B. In line with the luciferase assay, UBASH3B-dose 
dependently caused a decrease of the IFN response. For this, the induced expression of RIG-I 
as an ISG was used to reflect the strength of IFN induction. All these effects of UBASH3B 
were also observed with its phosphatase-mutant variant H391A, again indicating that its 
phosphatase function is not necessary for the observed effect on MAVS.   
 
 
Figure 26: Overexpression of UBASH3B causes a decrease in MAVS activation in HEK293T 
cells. HEK293T grown in a 12-well plate were transfected with MAVS (250 ng/ml) along with 
increasing amounts of UBASH3B-wt or its phosphatase mutant H391A (0/250/500/1000/1500 
ng/ml) for 24 h. The cells were lysed in RIPA buffer and after centrifugation of the lysate 
supernatants and the pellet, respectively were analyzed for the indicated proteins via Western 
blot. Shown is one representative blot out of three biological replicates. 
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3.2.8 The effect of UBASH3A/B deficiency on RLR signaling in murine bone    
         marrow-derived macrophages varies depending on the strength of the RLR  
         signal 
In order to see, if UBASH3B also effects the RLR signaling in other species, our group got 
access to primary cells of UBASH3A/B double knockout cells. For this purpose, bone marrow 
from wt and UBASH3A/B double KO mice (a kind gift of Prof. Christian Brandts, university 
hospital, Frankfurt) was isolated and used to generate bone marrow-derived macrophages 
(BMDMs). UBASH3B only KO mice were not available to us. However, as UBASH3A 
expression is thought to be restricted to lymphocytes, we expected the effect of UBASH3B to 
be the dominant effect in macrophages.  
The cells were stimulated with two different concentration of 3p-RNA (100 ng/ml or 500 
ng/ml) and mRNA levels of IFN-β and IP-10 were measured at different time points via qRT-
PCR (Figure 27). There was no difference for IP-10 and only a non-significant trend for higher 
induction of IFN-β in KO cells compared to wt cells when they were stimulated with 500 ng/ml 
3p-RNA. However, when stimulated with low amounts of 3p-RNA (100 ng/ml) UBASH3A/B-
double KO macrophages showed a significant increase in mRNA level at an early point after 
stimulation (3h) for IFN-β and at a late time point (12h) for IP-10. These results indicate that 
UBASH3B is likely to also play a role in the murine RLR signaling pathway, although the 
effect might be weaker than in human cells.  
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Figure 27: The effect of UBASH3A/B deficiency on RLR signaling in murine bone marrow 
derived macrophages varies depending on the strength of the RLR signal. BMDMs from wt 
or UBASH3A/B-KO mice were isolated, differentiated, plated in 96-well plate and stimulated for 
indicated time points with (A, B) 100 ng/ml or (C, D) 500 ng/ml of 3p-RNA. The isolated mRNA 
was analyzed via qRT-PCR for indicated cytokines and normalized to the house keeping genes 
actin and GAPDH (reference). Data are shown as mean ± SEM from 3 individuals per genotype.  
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4 Discussion 
4.1 The defective interfering genome is the main trigger of RIG-I during   
      infection with VSV 
In previous work of our group done by Andreas Linder, a specific DI genome was detected 
as a RIG-I ligand during infection with VSV by analyzing the RNA that co-immunoprecipitated 
with RIG-I 9 h after infection by next generation sequencing (NGS) (140). The present thesis 
could verify this finding by showing that the identified DI genome in our VSV stocks is mainly 
responsible for the induction of the immune response. VSV stocks without DI genomes seem 
to trigger the signaling via Leader/N readthrough transcripts.  
The NGS analysis allowed precise reconstruction of the DI genome with a size of 4719 bp 
and a complementary trailer region of 55 bp. The complementary region can form base pairs, 
a characteristic feature of copyback DI genomes, which then would fulfill the requirements 
for a perfect RIG-I ligand: it is 5´triphosphorylated as it was shown in the thesis of Andreas 
Linder and has a short double stranded part (13,25).  
As the particle size of DIs differ from full-length virus, DI genomes of VSV are well studied, 
due to the possibility to isolate them size-dependently by sucrose gradient and 
ultracentrifugation (142). However, the DI genome analyzed in this thesis was not described 
before. So far, five DI genomes of VSV are described in detail, that comprises one deletion 
DI, one snapback DI and three copyback DI genomes (143). It was already described that DI 
genomes are associated with an IFN response but so far, the precise mechanism for that have 
not been described for VSV. But in contrast to the copyback DI genome identified in this 
thesis, previous literature mainly described snapback DI RNA structures to induce an IFN 
response (144). Due to its long double-stranded part snapback DI genomes, however, rather 
carries features typical for an MDA5 ligand.  
For VSV we describe for the first time that a DI genome is the dominant RIG-I trigger during 
the replication cycle. In the last years other groups revealed DI genomes from different RNA 
viruses as RIG-I ligands that also have a 5´copyback structure. Strahle et al. described 
copyback DI genomes of Sendai virus to be potent activators of IFN and could show that IFN 
induction depends on the replication of DI genomes. They also showed that these copyback 
DI particles are much more potent interferon inducers than DIs with an internal deletion 
(145). Later these copyback DI particles were found to specifically bind to RIG-I in NGS 
analysis, whereas full-length genomes have not been detected at all (33). In contrast to our 
study they used untagged endogenous RIG for their IP. In another approach RNA species 
were analyzed by NGS that are specifically associated with the nucleoprotein of measles (MV-
N) and also found a copyback DI genome to be enriched. They could further show that the 
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IFN induction highly relies on binding of this DI genome to RIG-I (146). In line with that, DI 
genomes of MV were also found in RIG-I pull-downs after RNA-protein cross-linking and pull-
down of endogenous RIG-I (147).   
Hence, up to now copyback DI genomes are well described RIG-I ligands. However, the 
dependency on replication is still a matter of debate. Most of the studies investigating 
structural features of DI genomes that bind to RIG-I are done with in-vitro transcribed or 
isolated, naked DI genomes (148,149). The strong IFN activation by transfection of naked DI 
genomes was confirmed in our study. By transfection of size-fractionated RNA isolated from 
infected cells, we could show that the identified DI genome is responsible for most of the 
produced IFN (see Figure 6).  
However, under physiological conditions the DI genome as well as the full-length genome 
are usually encapsidated by the N protein that should avoid the formation of secondary 
structures and in this way avoid detection by RIG-I. In the process of replication, the N protein 
is removed from DI genomes which could make them accessible for RIG-I. We also assume 
such replication-dependent detection from our data: The application of CHX, a translation 
inhibitor, that allows infection and primary transcription but no replication, showed complete 
blockage of DI genome accumulation as well as IFN induction (Figure 4). The replication-
dependency of VSV DI genome detection was also shown in a study by Panda et al. (150). 
They developed a tool to independently investigate the effect of infection and replication by 
using a cell line that stably expresses the proteins N, P and L that are necessary for 
replication. They found, that the infection with DI particles is not sufficient to induce an IFN 
response but needs replication. In contrast, tenOever et al. showed that IFN induction is 
polymerase independent but only needs a certain threshold of ribonucleoprotein (RNP) to 
induce an immune response (151). Since we did not test higher viral titers for infection, it 
could be also possible that replication was just needed to reach this threshold.  
However, how the detection by RIG-I would occur without replication is still unclear. One 
possibility could be that some DI genomes are not fully protected by the N protein and expose 
RNA sites that can form complementary structure, which could also explain the difference 
between our study, the studies of Panda et al. and of tenOever et al. In line with this 
hypothesis, Weber et al. claim, that the incoming RNPs of different segmented (-)ssRNA, like 
La Crosse virus (LACV) and Rift Valley Fever virus (RVFV) serve as RIG-I ligand, because they 
have complementary naked 3´ and 5´ends that form panhandle structures (152). A mechanism 
that could also apply for copyback DI genomes. Another possible mechanism is given in a 
study showing, that ATP-dependent helicase activity of RIG-I itself is capable of removing 
viral proteins from the RNA for its detection (153). 
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Although we could clearly show, that a defined DI genome of VSV is the main trigger of RIG-I 
in the tested viral stock, further studies are needed to clarify if also encapsidated ones can be 
detected or if replication is truly needed.  
4.2 RIG-I ligands in the absence of defective interfering genomes 
While the DI genome could be detected as the main RIG-I ligand after infection with our VSV 
stocks, the question arose, if there are other ligands and what are the ligands, if DI genomes 
are absent. By serial dilution of the original viral stock we could eliminate the DI genome to 
the extent, that even after 24 h of infection it was barely detectable. However, this stock still 
induced an IFN response, although it was much weaker than with the original virus stock 
(Figure 5). That hinted towards additional immunostimulatory RNA species generated during 
VSV infection besides the DI genome. The data from the RNA fragmentation assay indicate 
that the full-length genome most likely is responsible for this immune response, because only 
the long RNA molecules that corresponds to the size of full-length genomes showed a slight 
immunostimulatory effect in the absence of DI genomes (Figure 6). We verified the correct 
size-dependent fragmentation by qRT-PCR assay and additionally shock-froze the RNA 
samples before loading on the gel. This should exclude secondary RNA structure formation 
that would lead to incorrect separation. Nevertheless, as discussed above, the 
immunostimulatory capacity measured in this assay relies on naked RNA, that can form 
secondary structures that do not naturally occur and serve as PAMP. Moreover, this assay 
only shows that long RNA molecules induce the immune response but does not look for the 
responsible receptor. Due to the length it could also be an MDA5 ligand.  
The analysis of the RNA that co-immunoprecipitated with RIG-I after infection with DI-
genome-low VSV stocks should have clarified this. This showed only a strong enrichment of 
leader/N sequences that could also hint towards the binding of the full-length genome. But 
in this case an equal enrichment of all other genome regions would be expected that was not 
detectable by qRT-PCR of different genomic regions (Figure 7). However, the data of Andreas 
Linder hints towards the binding of a small portion of full-length genome, since negative 
sensed RNA was found to be enriched by 3- to 5-fold along the whole genome after NGS 
analysis. Because the qRT-PCR assay used in the present study also detect mRNAs, the small 
amounts of genomic RNA could be simply underrepresented. Although the full-length 
genome might slightly contribute to RIG-I activation, the strong enrichment of the leader/N-
readthrough speaks in favor of this RNA species being the main ligand of RIG-I in the absence 
of DI particles.  
This result is in line with a study that identified RIG-I ligands during MV infection with NGS 
and found besides DI genomes leader/N readthroughs to be enriched (147). Another recent 
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study also found the leader/N readthrough to be the main inducer of IFN via RIG-I. They 
identified the leader/N RNA as a 1.8 kb long RNA that is 5´triphosphorylated and 
3´polyadenylated. It associated with RIG-I in antiviral stress granules. They could show the 
same for two other non-segmented (-)ssRNA viruses, for VSV and Respiratory syncytial virus 
(RSV), indicating that this is a general mechanism of this virus family (154). Such readthrough 
RNAs are derived from transcription and thus are not wrapped by N proteins. Whether the 
leader/N RNA forms intramolecular double-stranded structures or pairs with the full-length 
genome was not addressed and would be an interesting question for further studies.  
Our RNA fragmentation assay showed an immunostimulatory capacity only for the long 
fractions, which could be a result from binding of the readthrough to the full-length genome 
after RNA purification. The same finding was made by Rehwinkel et al., who used the same 
fragmentation assay after infection with Sendai virus or Influenza. They further used primer 
extension for identification, but this assay does not allow to distinguish between DI and full-
length genome which could have led to the misinterpretation of the full-length genome as the 
main ligand for RIG-I (24). They lack the detailed analysis of RNA co-immunoprecipitated 
with RIG-I by NGS. Their interpretation is also contradicted by Baum et al. who could show 
by NGS analysis, that only DI genomes of Sendai virus but no full-length genome bind to 
RIG-I (33). 
However, for influenza the finding of Rehwinkel et al. could also be due to its nature as a 
segmented (-)ssRNA virus. Weber et al. had shown that influenza genome segments can act 
as RIG-I ligands. They claim that the genome segments of influenza, even when they are 
protected by viral proteins can form a panhandle structure due to their high complementary 
termini, but that this is not the case for non-segmented (-)ssRNA viruses such as Sendai or 
VSV (152).  
All in all, this led to the assumption that the leader/N readthrough of VSV could trigger RIG-I 
in the absence of DI genomes probably via formation of double-stranded intermediates by 
binding to the complementary full-length genome. To test this hypothesis, however, further 
experiments will be needed.  
4.3 Physiological role of defective interfering genomes 
The main finding of this part of the thesis is the strong contribution of DI genomes to the IFN 
response upon VSV infection. This poses the question, if and how this could be 
physiologically relevant.  
Since more and more DI genomes are detected in human specimens (see 1.5) it is believed 
that they occur in natural infection and are not only cell culture artefacts. Because of their 
ability to induce IFN, they can restrict viral replication, thus limiting the outbreak of the 
4 Discussion 76 
 
disease and induce a proper immune response. Although the physiological role of the 
accumulation of DI genomes after infection, i.e. if it also has advantages for the virus, is still 
not clear, DI genomes have gained much interest as a potential adjuvant in vaccines. 
This potential of DI genomes was shown in a study that compares DI-low and DI-high viral 
stocks of a vaccine strain of MV (155). They found, that infection of monocyte-derived DCs 
with DI-high stocks induced more IFN that correlated with a greater DC maturation. They 
further showed, that the wt virus strain behaved similar as the vaccine strain, when the DI 
genomes were diluted out. This is one study demonstrating that DI genomes can highly 
contribute to vaccination efficiency as it was already shown for other viruses, like Sendai 
virus (29). It was further shown that a DI genome of Sendai is capable via the stronger 
activation of DCs to induce a stronger activation of naïve CD8+ T-cells and to enhance 
antibody production (156). For different live-attenuated vaccines, such as MV, poliovirus or 
influenza a high amount of DI genomes have been found (157). This further suggests a 
contribution to the efficacy of vaccination.  
The identification and characterization of DI genomes of VSV, like the one identified in the 
present study can help to find a highly potent DI genome that can be used as an adjuvant for 
vaccines by triggering the RLR pathway. Moreover, as VSV is already used as a vector for 
different replication-competent vaccines, such as the vaccine against the Ebola virus (EBOV-
VSV) (158), the determination of amount and type of DI genomes in these vaccines would be 
helpful to get more reproducible results on vaccination efficacy. VSV is further developed for 
oncolytic tumor therapy. Here, the efficacy of cell lysis and induction and reactivation 
respectively of immune responses against the tumor cells highly depends on the capacity of 
the virus to replicate and to induce cytokines, which is in turn influenced by the amount of 
DI genome. Thus, the determination and purposeful use of DI genomes could help to improve 
this therapy, which has to our knowledge not been investigated so far. 
4.4 The specificity of APEX in the MAVS-APEX fusion protein  
The second part of the thesis presented here focused on MAVS, the downstream adapter 
molecule of RIG-I and MDA5 and identified and characterized new interaction partners to 
gain further insights into the regulation of this antiviral pathway. 
The list of MAVS interaction partners is constantly growing. So far most often conventional 
methods like co-immunoprecipitation and yeast-two-hybrid screens have been applied for 
their identification or verification. Since APEX-mediated labeling is applicable to living cells, 
it acts in the most physiological environment and has the ability to catch weak and transient 
interaction partners at a defined time point. This method is therefore highly promising to 
identify further important interactors, that have not yet been described in MAVS signaling.  
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At the time we started to use APEX, there were just two publications out describing the 
method in proof-of-principle studies. It was demonstrated that APEX is suitable for labeling 
subcellular proteomes that are enclosed by membranes, such as the mitochondrial matrix 
and the IMS (128,132). Thus, the first question that needed to be answered, was how specific 
the labeling was in the cytoplasmic part, where APEX is located when fused to MAVS. 
The labeling radius of biotin phenoxyl radicals was suggested to be less than 20 nm. This 
number arose from electron microscopy experiments on fixed cells (159). Rhee et al. assumed 
that it can be even smaller in living cells, because of endogenous radical quenchers (e.g. 
gluthathione). By fusion of APEX to localization sequences targeting the molecule to different 
organelles (i.e. nucleus, mitochondrial matrix, IMS, ER), they could show by confocal imaging 
and Western blot analysis, that each construct biotinylates different subsets of proteins in the 
expected compartment. Furthermore, they targeted APEX to different subcellular 
compartments, but with APEX facing the cytosol. Even these constructs displayed a distinct 
biotinylation pattern. This was the first hint that APEX works also specifically in the cytosolic 
part, when it is bound to a membrane (128). 
With our constructs we could confirm this finding for cytosolic APEX: As expected, all APEX-
MAVS constructs as well as the APEX-TM construct showed the same biotinylation pattern, 
since they all have the same localization at the OMM facing the cytosol. This was clearly 
distinct from the mito-APEX construct from the study of Rhee et al. that is localized in the 
mitochondrial matrix and was used by us as a control (128). While the improved APEX2 
enzyme was used in our MAVS constructs, the mito-APEX construct bears the older version. 
This might explain the difference in biotinylation intensity that we observed (Figure 9).  
Additionally, the confocal imaging supports the specificity of APEX, since the biotinylation 
was highly enriched at mitochondria, although it was not as restricted as for the control 
construct mito-APEX. Reasons for the observed background biotinylation could either be that 
the radical diffuses during the one minute the APEX reaction lasts and biotinylates a small 
fraction of distant proteins or that proximity labeled proteins diffuse in the cytosol after 
biotinylation. This question was already addressed by Hung et al., when they used IMS-
targeted APEX, because the phenoxyl radicals are theoretically able to diffuse through the 
OMM. After MS analysis they found that also cytosolic proteins were biotinylated, mostly 
those that reside near the mitochondria. They concluded, that a small portion of the radicals 
diffuse and label cytosolic proteins (132). From this study we assume that this is also the case 
for our constructs.  
Although the overall biotinylation pattern for APEX-TM and APEX510MAVS was the same 
under homeostatic conditions, Western blot analysis of known MAVS interactors after 
streptavidin pull-down revealed, that both constructs biotinylate different proteins (Figure 
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11). Whereas for APEX-TM each protein was biotinylated in the unstimulated condition, 
TRAF3 and TBK1 were only detectable upon stimulation in APEX510MAVS. Moreover, GAPDH 
was much more enriched for APEX-TM, indicating a stronger background biotinylation with 
this APEX-TM construct compared to APEX510MAVS. Reasons for that may be the stronger 
enzyme activity of APEX in the APEX-TM construct due to a lack of steric hindrance by an N-
terminal fusion protein. APEX within the APEX-TM construct is freely exposed into the 
cytosol, whereas in the APEX510MAVS construct it is enclosed by the helicase and signaling 
domain of MAVS, which is likely to cause differences in the biotinylation capacity.  
However, the most striking difference of both constructs was observed by confocal imaging 
upon 3p-RNA stimulation. Both, APEX510MAVS and APEX-TM induced the same biotinylation 
pattern in the unstimulated condition. But 1 h after 3p-RNA treatment, APEX510MAVS showed 
a completely different pattern with characteristic dots (Figure 12). Because this was not 
observed with APEX-TM, we assume that this pattern is specific for MAVS and not for any 
mitochondrial changes upon stimulation. Furthermore, this pattern was only observed upon 
MAVS activation with 3p-RNA, but not after stimulation with untransfected pIC, that signals 
independent of MAVS (data not shown). This further supports that it is a MAVS-specific 
change in the biotinylation pattern and represents activated polymerized MAVS and its 
associated signaling complex. The comparison of APEX-TM and APEX510MAVS indicates, 
that APEX works not only specific for different subcellular sites but also for specific 
membrane bound proteins. 
APEX510MAVS thereby presents a new tool to study dynamics in MAVS signaling, that have 
not been possible before. So far, MAVS activation could only be detected with semi-
denaturating detergent agarose gel electrophoresis (SDD-AGE) that allows to visualize MAVS 
polymers after lysing the cells. In contrast, simple MAVS staining in confocal microscopy 
cannot differentiate between monomeric or oligomerized MAVS. Thus, detection of MAVS 
activation with APEX can be applied to study the kinetics of MAVS activation and interaction 
progress with other molecules. We could show, that TBK1 is highly associated with the biotin 
dots after 1 h of stimulation and gets subsequently released, whereas the activated MAVS 
remains stable. This also further confirm that the biotin dots indeed reflect MAVS signaling 
complexes. This fits to the report from Pourcelot et al., showing that TBK-1 is activated in 
interaction with MAVS, but that activated TBK1 is mostly associated with the Golgi apparatus 
(160). We did not look for colocalization of TBK1 with the Golgi, but at least the dissociation 
from MAVS after activation is consistent with our result.  
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4.5 Control conditions for mass spectrometric analysis 
Although, APEX510MAVS seems to work specifically for MAVS associated proteins, there is 
some background biotinylation that needs to be eliminated in order to identify true positive 
interaction candidates. As it was shown in former APEX studies, choosing the right controls 
is crucial to gain high specificity.  
In the initial APEX publication that identified the mitochondrial matrix proteome, a control 
that simply lacked the biotinylation process was sufficient to gain a specificity of > 94%, 
because the biotinylation is highly restricted to this membrane enclosed space (128). The 
same control for the mapping of the IMS proteome just gave a specificity of 40% for 
mitochondrial proteins. As discussed above, the permeability of the OMM for small molecules 
like the phenoxyl radicals produced by the APEX reaction leading to some cytosolic 
background has probably caused the reduced specificity. By including a second control, the 
APEX-NES that is unspecifically expressed in the cytosol, they were able to exclude the false 
positive cytosolic proteins and increased the specificity to 87% with prior mitochondrial 
annotation (132).  
Independent from our study, more recently the group of Hung et al. published a paper where 
they used a construct (APEX2-OMM) that is exactly the same as our APEX-TM construct, 
meaning that APEX is fused to the TM domain of MAVS at the amino acid 510. The authors 
used this fusion protein to map the proteome of the OMM. Although they overall detect more 
than 4000 proteins, by again using APEX-NES as a spatial control, they were able to identify 
137 proteins that are specific for the OMM (161). We could find 29 proteins from this list in 
each of our unstimulated APEX-TM replicates and 44 proteins of their OMM proteome were 
detected in at least one of our APEX-TM replicates. Reasons for this small number of 
overlapping proteins could be the amount of overall detected proteins. Whereas we detected 
approximately 800 proteins per replicate (see Figure 14B), Hung et al. detected more than 
5000 proteins per replicate. As we used comparable amounts of protein for mass 
spectrometric analysis, it is unlikely that protein quantities caused this difference. One major 
difference between our analyses was the quantification method. Whereas we used label-free 
quantification, Hung et al. used SILAC (stable isotope labeling with amino acids in cell 
culture) for quantification. They further used another cell line (HEK293T) which could also 
cause the differences. 
In the first study describing protein interaction networks with APEX it was further 
demonstrated, that even if the protein of interest changes its localization upon signaling 
activation, it is possible to identify true positive interactors by choosing the right control. 
They coupled APEX to a GPCR and could track it over time after activation. Similar to our 
APEX-TM, in their control condition APEX was fused to a respective localization sequence 
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(plasma membrane, endosome or cytosol) and was used for normalization at these time points 
when the GPCR was localized to this compartment. Since they used a well described GPCR 
they could confirm that this approach is specific and further revealed new interaction partners 
(137).  
Similar to this study, we were not primarily interested in the proteomic composition of a 
steady-state situation, but rather in the proteomic alteration upon RLR activation. For this 
question, one obvious control was the unstimulated situation in the APEX510MAVS cells. This 
should control for all background biotinylation and should only identify those proteins, that 
translocate into the vicinity of MAVS upon its activation. As a spatial control, we used the cell 
line APEX-TM in the unstimulated state and upon MAVS activation. This control was 
supposed to identify proteins that translocate to the mitochondria but independent of 
interaction with MAVS. Since we could not detect any significant changed protein in this 
control, all the proteins that are significantly altered in the APEX510MAVS cells upon 
stimulation were considered to be MAVS-specific. 
4.6 Analysis of the identified MAVS interaction network 
The analysis of our MS data revealed 31 proteins that translocate to the MAVS signaling 
complex 1 h after stimulation with 3p-RNA. Since many interaction partners of MAVS are 
already well described, we expected to find some of these previously identified interaction 
partners in our assay. 
Indeed, we were able to detect 11 proteins that are described as part of the MAVS 
signalosome. TBK1 showed the highest significance which is in line with the Western blot 
analysis (Figure 11) and with the literature, characterizing TBK1 as highly important for 
activation of downstream signaling. In contrast to the Western blot data, we could not detect 
TRAF3, but instead found TRAF2 and TRAF6 and all essential components to activate the 
NFkB signaling branch (IKKα, IKKβ, NEMO and TANK). Further proteins that are directly 
linked to the MAVS signalosome is the LUBAC complex consisting of HOIP (RNF31), HOIL 
(RBCK1) and SHARPIN, that were all significantly enriched. However, up to now, the actual 
role of the LUBAC complex in MAVS signaling is not clear. One report claims that it acts 
redundantly to TRAF molecules by transferring ubiquitin chains to MAVS if TRAF molecules 
are missing (79). In contrast, Belagnoui et al. described a negative regulatory function 
through ubiquitination of NEMO that subsequently inhibits MAVS-TRAF3 interaction (162). 
More recently TAX1BP1, also identified as interactor in our assay, was published to directly 
interact with MAVS and recruit AIP4 for MAVS degradation (163).  
Although, several important proteins known to act downstream of MAVS were found within 
the candidate proteins, the essential upstream activator RIG-I was missing. In line with the 
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Western Blot data, it got biotinylated upon APEX activation, but the amount did not change 
after stimulation, no matter at which time point after stimulation. This raised the possibilities 
that RIG-I is not translocated to MAVS but is always in close surrounding and just needs an 
activating trigger or that activated RIG-I is not biotinylated because it binds to the CARD 
domain of MAVS that is distant from APEX. Since the predicted labeling radius of APEX 
should cover this distance, however, the latter possibility is not likely. Speaking in favor of 
the first hypothesis is, that in MS data of the control cell line APEX-TM RIG-I was not detected 
at all, although that contradicts the Western blot data (Figure 11). The common knowledge 
is, that RIG-I is translocated to MAVS (63,76), which speaks against our finding. However, 
this conclusion was always drawn after IP of RIG-I or after purification of mitochondrial 
membranes. It could be that only upon binding of the CARD domains of RIG-I and MAVS the 
interaction was strong enough to sustain the detection methods, whereas their sole proximity 
was not detectable with these methods. Since confocal microscopy could also not clearly 
show any redistribution upon RIG-I activation (data not shown) further experiments are 
needed to test this hypothesis.  
Three additional proteins were detected after MS analysis that have an indirect link to the 
MAVS signaling platform and are described to play a role in NFkB activation (OPTN, BIRC2, 
TNIP1). Another three proteins are also linked to MAVS signaling but have not been within 
the cluster identified by the online tool string-db (Figure 16). N4BP1 is indirectly linked to 
MAVS through its interaction with AIP4 that in turn cause degradation of MAVS (93) and 
DRP1 and OPA1 are important for mitochondrial dynamics and have been shown to influence 
RLR signaling (98).  
The remaining 14 proteins have no described connection to MAVS-dependent signaling yet. 
Interestingly, several proteins (IMMT, CHCHD3, ATAD3A) and OPA1 are located to the inner 
mitochondrial membrane (IMM) and together with TBC1D15 are important for mitochondrial 
morphology. Even though this needs to be further evaluated, if these proteins directly interact 
with MAVS or at least come in close proximity to MAVS due to mitochondrial rearrangement, 
the presence of these proteins in this data set supports the hypothesis that mitochondrial 
dynamics is a highly important process induced by as well as influencing MAVS activation as 
described in 1.8.  
Taken together, we could convincingly show that APEX is suitable to detect MAVS interaction 
partners or at least proteins of the MAVS signaling complex. This makes it an interesting tool 
to further study MAVS signaling. To draw a dynamic picture of components of the MAVS 
signaling complex, the MS analysis could be repeated at later time points. Further interesting 
questions that could be tackled with the APEX method are, how physiological virus infection 
influences the signalosome and how it differs between viruses or whether there are any 
4 Discussion 82 
 
differences in the kinetic and composition of the MAVS signalosome between activation via 
RIG-I and MDA5, respectively.   
4.7 UBASH3B is a negative regulator of RIG-I like receptor signaling 
UBASH3B, also known as Sts-1 (suppressor of T-cell signaling) or TULA-2 (T-cell ubiquitin 
ligand) is described as regulator of different cellular functions. It has three known functional 
domains: the ubiquitin-binding domain (UBA), a Src-homology 3 (SH3) domain and a 
histidine phosphatase domain, that is specific for tyrosine residues. Its mode of action is 
thought to be defined by these domains: UBASH3B binds via its UBA domain to 
ubiquitinylated proteins, while the SH3 domain mediates the interaction with SH3-binding 
proteins. The active phosphatase domain then exerts its function on phosphorylated tyrosine 
residues. This protein family has a second member, UBASH3A (Sts-2, TULA), displaying the 
same function, but with a lower phosphatase activity. Furthermore, it is only expressed in 
lymphoid cells, whereas UBASH3B is ubiquitously expressed (164). 
UBASH3B is described as a regulator for signaling receptors, like the T-cell receptor (TCR) 
and the epidermal growth factor receptor (EGFR). It has a negative regulatory function on 
TCR signaling by dephosphorylation of Zap-70 (165,166), whereas it has a stabilizing function 
on activated EGFR. Two groups showed, that it acts indirectly via dephosphorylation of the 
E3 ligase c-Cbl, a well described interaction partner of UBASH3B. C-Cbl was found to 
constantly interact with UBASH3B and upon ligand binding UBASH3B is recruited to the 
EGFR via c-Cbl. As the counter part of c-Cbl, which ubiquitinates and degrades EGFR, 
UBASH3B inhibits this degradation process (167,168).  
Together with the data from MS (Figure 15) and the initial KO screen (Figure 17), these 
characteristics made UBASH3B a highly promising candidate in regulating MAVS, a 
membrane bound receptor, such as TCR or EGFR.  
To analyze the function of UBASH3B, we decided to use a CRISPR/Cas9-mediated KO-based 
system. The invention of CRISPR/Cas9 has brought a revolutionary tool into the labs to easily 
knock out a gene of interest in cell culture. However, this method has some pitfalls one need 
to be aware of, when working with this system: The sgRNA can have off-target effects. If the 
sgRNA is not specific enough, it can bind to different loci and cause background mutations. 
To circumvent this, we used the online tool http://chopchop.cbu.uib.no, that predicts off-
target effects, to design sgRNAs. We further used the enhanced Cas9 (eCas9), that has a 
mutation, allowing the cleavage of DNA only when the sgRNA is totally complementary to the 
target site (169). To further exclude off-target effects we used two different sgRNAs to 
generate KO clones.  
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The second major problem is not directly related to the CRISPR/Cas9 system, but to the 
process of generating single cell knockout clones that are used for KO studies. Especially 
when working with tumor-derived cell lines, such as the 1205 Lu cells, random mutations 
accumulate during the expansion process of generating SCC, that are not caused by sgRNA-
mediated off-target. This was an observation we made in our group after exome sequencing 
of two different SCC generated with the same sgRNA. We further saw this phenomenon in 
the initial screen of different gene KOs, where some SCC carrying the same KO genotype 
concerning the target gene behaved differently (Figure 17). To avoid this error, we worked 
also with cell batches, that where treated with the CRISPR/Cas9 system and selected for Cas9 
expression but were not subjected to the process of single cell cloning. A prerequisite to use 
this approach is a high efficiency of the sgRNA, that we could show by Western blot analysis. 
Additionally, we used knockout cell lines generated from patient derived fibroblasts, that 
were immortalized by transduction of hTERT. These cell lines have no tumorigenic 
background and therefore are supposed to be genetically more stable. This should reduce 
the accumulation of random mutations during SCC expansion. Fibroblasts are further 
described to be biallelic, a feature that makes it easier to identify genetically complete 
knockout SSC than in multiallelic tumor cell lines. 
Consistently, both sgRNAs and clones derived from both cell lines (1205 Lu melanoma cells 
and immortalized fibroblasts) showed the same phenotype upon 3p-RNA stimulation: a 
higher induction of different cytokines and earlier and stronger MAVS activation, that was in 
line with earlier induction of the two signaling branches of IRF-3 and NFkB activation. These 
phenotypes were strongly observed at early time points after activation (up to 6 h), whereas 
at later time the KO and wt phenotypes converged again.  
From these results we concluded a negative regulatory function for UBASH3B, that is 
especially important early on when the RLR signaling pathway is activated. Interestingly, 
already after 1 h of 3p-RNA stimulation, the time point the candidate proteins have been 
identified by our APEX screen, loss of UBASH3B had a direct impact on MAVS activation as 
shown by increased aggregate formation of MAVS. This was in line with the results obtained 
in HEK293T cells, showing that overexpression of UBASH3B along with MAVS decreased the 
IFN- and NFkB signaling in luciferase reporter assays (Figure 25) and also decreased the 
amount of MAVS aggregates (Figure 26). UBASH3B did not influence the signaling further 
downstream, at least not on the IRF3 signaling branch, as shown with the overexpression 
together with TBK1 or IRF3-5D.  
These results suggest a direct interaction of UBASH3B with MAVS or one of the early 
interactors, like TRAF molecules that play a role on the activation of both, IFN and NFkB 
signaling path. Even more, preliminary IP assays verified the interaction of MAVS and 
UBASH3B (data not shown). These results could be further confirmed in the doctoral project 
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of Corinna Meyer-Gehlen. However, if this interaction is direct or via linking proteins still 
needs to be figured out.  
One of the first crucial steps for MAVS activation is its ubiquitination by TRAF molecules. 
UBASH3B could possibly act, by binding to this ubiquitin chains and either dephosphorylates 
itself or another protein in the close surrounding leading to downregulation of the signaling. 
To test if dephosphorylation is the mechanism, how UBASH3B downregulates MAVS 
signaling, we generated a phosphatase-dead mutant (H391A). This mutation is described to 
highly decrease the phosphatase activity (141). In our case this mutant behaved like the wt 
protein by reducing the antiviral signaling. Reasons for that could be, that this function of 
UBASH3B is not important and that just the binding is sufficient to e.g. recruit other signaling 
molecules that exerts the function. In this case UBASH3B would function as a bridging 
protein. Since we relied on the phenotype described in the literature for the H391A mutation 
and did not test for residual phosphatase activity in this mutant, it could be that some residual 
phosphatase activity is sufficient for the dephosphorylation. In further experiments it will be 
tested by MAVS-IP, if its tyrosine phosphorylation is different between wt and KO cells upon 
RLR activation. MAVS itself bears 10 tyrosine residues that would be possible targets for 
UBASH3B. In a study by Wen et al. the importance of all these residues were tested in 
mutation-based screen. They replaced every tyrosine by phenylalanine, leading to loss of this 
phosphorylation site by keeping the protein structure intact. Only the mutation Y9F was found 
to highly affect the immune response. Mechanistically, the loss of this phosphorylation 
impaired the binding of TRAF3 and TRAF6 (88). Up to now, the responsible kinase and 
phosphatase are unknown, which makes the T9 residue an interesting candidate to look for 
interaction with UBASH3B.  
As mentioned above, UBASH3B constitutively interacts with c-Cbl, a protein that is also 
described in regulating the RLR pathway and could thus be an interesting link. It was found 
that c-Cbl is recruited to RIG-I via Siglec G and marks RIG-I by K-48 linked ubiquitination for 
degradation (170). Since UBASH3B counteracts c-Cbl activity, the KO of UBASH3B would 
decrease the activation of MAVS because more RIG-I would be degraded – the opposite effect 
of what we found. Thus, this mechanism does not seem to cause the phenotype.  
Another described molecule that potentially links UBASH3B to MAVS is Src. This tyrosine 
kinase was found to be a substrate of UBASH3B (166). A recent study identified Src to be 
important for TBK1 phosphorylation at a specific tyrosine residue that facilitates its 
autophosphorylation and subsequent IRF3 activation. Interestingly, by performing in vitro 
GST-pull-down assays they found that Src and TBK1 do not interact directly. Instead, Src 
directly interacts with the proline-rich region of MAVS via its SH3 domain (171).  
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This mechanism would fit to the negative regulatory function of UBASH3B we observed: 
UBASH3B is a counterpart of Src, that inactivates it by dephosphorylation. Missing UBASH3B 
could lead to excessive Src activity that in turn leads to stronger activation of TBK1. Indeed, 
we could observe stronger phosphorylation in the KO cells upon RLR activation.  
But part of the study of Li et al. do not fit to our observation: Li et al. showed that by chemical 
inhibition of Src the phosphorylation of IκBα is not affected, whereas we also observed 
enhanced activation in the UBASH3B-KO. However, it may be that UBASH3B has an 
additional role on another kinase than Src, that regulates the NFkB signaling. The hypothesis 
that UBASH3B mediates its effect on the RLR signaling via this Src-mediated phosphorylation 
could be tested by creating double KO cell lines in which the additional KO of Src should 
reverse the phenotype of the UBASH3B-KO (Figure 28). 
Another interesting function of UBASH3B in the context of antiviral signaling is its influence 
on the interferon signaling. It was found, that the high level of IFN-α in B cells of patients 
with Systemic lupus erythematodes (SLE) correlated with increased level of UBASH3B. The 
authors could show that overexpression of UBASH3B in human B cells leads to increased 
expression of ISGs like OAS1, IFIT1 and IFI44 after IFN-α treatment. This effect also resulted 
from the interaction of UBASH3B with c-Cbl. They showed that c-Cbl inhibited the UBASH3B 
promoted STAT1 phosphorylation and concluded that UBASH3B enhances IFN-α-induced 
JAK-STAT signaling via c-Cbl (172). This finding could explain our observation that at later 
time points (9 and 12 h) after 3p-RNA stimulation the KO cells showed no enhanced signaling 
anymore as shown for the expression of IFN-β and IL-6 (Figure 19) as well as for the 
aggregation of MAVS and activation of TBK1, IRF3 and IκBα (Figure 20). The RLR-dependent 
IFN induction starts approximately 6 h after signal activation leading to an autocrine 
mediated induction of JAK/STAT signaling. The positive regulatory function of UBASH3B in 
this interferon loop-pathway could then compensate for its opposite role in MAVS signaling.  
Although most of the results fits to the hypothesis that UBASH3B directly or indirectly acts 
on MAVS to delay and reduce its activation, the main discrepancy is the missing 
reconstitution of the wt phenotype after UBASH3B overexpression in the 1205 Lu cells. In 
the experiment with transient overexpression of UBASH3B (see Figure 23), the missing effect 
could result from the low transfection efficiency. The 1205 Lu cells just reach a transfection 
rate of 20%, that might be too small to see the regulatory effect of UBASH3B. Instead, using 
HEK293T cells we could detect the inhibitory effect of UBASH3B, maybe because the 
transfection efficiency is much higher in these cells. Furthermore, we analyzed the data from 
RNA sequencing of the 1205 Lu cells for different splicing variants. There is just one isoform 
of UBASH3B expressed in these cells, hence overexpression of the wrong variant could not 
be the reason for the failed rescue.   
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Another explanation for the lacking rescue could be, that the insertion via exogenous DNA 
does not mimic the physiological amount and pattern of expression in one cell. To control for 
that, we generated a stable dox-inducible cell line with every cell expressing UBASH3B under 
control of a dox-inducible promoter. Although, we induced different amounts of UBASH3B 
and checked the expression pattern by confocal microscopy, showing a cytoplasmic 
distribution as for the endogenous protein (data not shown), we could not rescue the 
phenotype. The most likely explanation for this unexpected result comes from a recently 
published paper: By searching for small molecule inhibitors for UBASH3B, Zhou et al. found 
that doxycycline was one of the most effective compound to inhibit phosphatase activity of 
UBASH3B (173). The half maximal inhibitory concentration (IC50) is 4.1 µM (1.8 ng/ml), 
which is much less then dosages we used (10 and 100 ng/ml) for UBASH3B induction. Since 
the effect of UBASH3B on MAVS might be dependent on its phosphatase function, it is likely 
that the inhibition via doxycycline caused the lack of reconstitution. Thus, it is necessary to 
use another system for induction of UBASH3B expression to show that the knockout 
phenotype is reversable.  
However, the dose dependent overexpression revealed another interesting phenomenon: 
Although we could not detect any effect on the immune signaling, UBASH3B mRNA, even 
though it was exogenous introduced with the help of the pLVX vector using the dox-inducible 
promoter, was down-regulated upon 3p-RNA stimulation. This indicates a post-
transcriptional regulation of the mRNA by a factor that is induced upon RLR signaling 
activation. It could be that an ISG that is induced upon 3p-RNA stimulation and drives mRNA 
degradation of UBASH3B or that a microRNA is induced which can destabilize the mRNA. It 
is further possible that the promoter activity is influenced, here most likely by the doxycycline 
concentration. Since the unstimulated condition was incubated with doxycycline as long as 
the sample stimulated for 12 h with 3p-RNA, we can rule out, that the reduction of 
doxycycline in the medium over time caused the effect. 
By analyzing TCGA (The cancer genome atlas) data, a recent study found that the expression 
level of UBASH3B is negatively correlated with its methylation state (174). This modification 
could also explain our observation although nothing is known about the regulation of this 
methylation. The authors speculate that the Estrogen receptor 1 (ESR1) could be a regulator, 
since the UBASH3B mRNA level inversely correlated with ESR1 protein level. The lack of 
Estrogen receptor together with increased UBASH3B level is one hallmark of triple-negative 
breast cancer (TNBC). It was found that UBASH3B has a direct oncogenic function by 
enhancing the EGFR signaling leading to uncontrolled cell proliferation (175).  
The finding, that RLR signaling activation can decrease UBASH3B level, leads to the 
hypothesis that 3p-RNA treatment could be an efficient therapy against TNBC. On the one 
hand the RLR activation could induce tumor-specific apoptosis and subsequently adaptive 
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immunity to fight the cancer as it was already shown for several tumor entities. On the other 
hand, the additional decrease of UBASH3B could reduce its tumorgenic character.  
Moreover, UBASH3B is an interesting therapeutic target to treat different infectious diseases. 
In mice lacking both homologues UBASH3A and UBASH3B it was found that they are 
profoundly more resistant to fungal infection with Candida albicans as well as to bacterial 
infection with Francisella tularensis (176,177). The better survival corresponds to stronger 
induction of different proinflammatory cytokines at early time points after infection (e.g. IL-4, 
IL-10, IL-13 in the spleen after F. tularensis infection and IP-10 in the kidney after C. albicans 
infection). The authors hypothesize that UBASH3A and UBASH3B negatively control innate 
immune signaling pathways. In their model UBASH ‘tips the balance of effector activation in 
such a way as to favor improved host cell responses and enhanced microbial clearance’ (176).  
This is exactly what we also observed in the UBASH3B single KO in human cell lines after 
mimicking a viral infection with 3p-RNA with MAVS being this effector. To figure out, if viral 
infection in the double-KO mice also shows a phenotype, we initially stimulated BMDMs with 
3p-RNA. We observed a slight effect with increased IP-10 and IFN-β induction in the KO cells 
when using small amounts of 3p-RNA (100 ng/ml). With higher concentration (500 ng/ml) 
these differences between KO and wt were less pronounced (see Figure 27). Thus, BMDMs 
showed the expected phenotype, but to a less extent compared to human cells. The study of 
Parashar et al. indicates that BMDMs might not be the best cell population to study the 
function of UBASH3B. They also used these cells for F. tularensis infection ex vivo and could 
not find any differences in bacterial clearance but found that monocytes could restrict the 
growth (176). Therefore, it would be interesting to test also this cell population with 3p-RNA 
stimulation and to infect UBASH3A/3B double- and single KO mice with a virus that signals 
via MAVS, such as VSV. That would help to find out, if UBASH3B has a physiological role 
during virus infection. 
All in all, with loss-of-function experiments and overexpression we were able to show, that 
UBASH3B has a negative regulatory function on the RLR pathway. From the data we assume 
that UBASH3B influences the signaling on the level of MAVS. To elucidate the mechanism, 
however, further experiments are needed to, e.g. clarify if MAVS is targeted directly or if 
there are any bridging protein involved. Since the phenotype of UBASH3B-KO shows that it 
has a modulatory influence mainly at the onset of signaling, it needs to be figured out if this 
function is relevant in a physiological context, like a virus infection in vivo.  
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Figure 28: Possible mechanism how UBASH3B downregulates RLR signaling. (A) Schematic 
representation of UBASH3B with its functional domains: the ubiquitin-binding domain (UBA), 
the SH3 and phosphatase domain, as well as the point mutation that was used to diminish the 
phosphatase activity. (B) Downregulation of MAVS activity could be caused by direct binding of 
ubiquitin chains of MAVS thereby dephosphorylating MAVS tyrosine residues, by modification 
of other MAVS interactors causing the inhibition of MAVS aggregation or via the interaction of 
UBASH3B with Src that would lead to less TBK1 phosphorylation. Finally, UBASH3B leads to 
formation of less MAVS aggregates and subsequently less activation of IRF3 and IκBα. For 
further description see 4.7. 
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5 Summary 
The induction of an adequate innate immune response after viral infection is crucial to 
constrain viral replication and to activate the adaptive immune system. RIG-I-like receptors 
(RLRs) detect viral RNA patterns in the cytosol and are crucial for detection of many RNA 
viruses. RLR ligands are under development as vaccine adjuvants and as anti-tumor agents. 
Conversely, gain-of-function mutations in the RLR pathway have been identified as the cause 
of inborn autoinflammatory syndromes. 
The detected RNA pattern and many important players of the RLR signaling pathway have 
been already defined. However, the actual RNA species that trigger RIG-I in the natural 
course of infection are less characterized and it is still incompletely understood how this 
signaling is orchestrated and downmodulated to induce a balanced immune response. 
We therefore set out to identify the ligands of RIG-I during infection with vesicular stomatitis 
virus (VSV) as a model virus of the Mononegavirales, that are known to be mainly detected 
by RIG-I. In a former project of our group, we had been able to show that one defined copy-
back DI genome associated with RIG-I. After analysis of RIG-I bound RNA by deep sequencing 
the precise sequence of this DI genome was identified and showed perfect characteristics of 
a RIG-I ligand with a short double-stranded part and a 5´triphosphate moiety.  
In the work presented here we could extend this data and show that the identified DI genome 
replicates in the course of infection. Through serial dilution of the viral stock, the DI genomes 
were diluted out allowing the comparison of DI-high versus DI-low viral stocks. This revealed 
that DI-high stocks were much more potent in inducing an interferon (IFN) response. An RNA 
fragmentation assay further showed that the RNA with the highest immunostimulatory 
capacity in our DI-high stocks has a size that matches the size of the identified DI genome 
(4719 bp), confirming that the binding of the DI genome to RIG-I triggers the antiviral 
signaling. In the absence of DI genomes, the RNA fragmentation assay and RIG-I IP indicated 
that leader/N readthrough sequences and - to a smaller extent - the VSV full-length genome 
induces the immune response via RIG-I.  
In the second part the thesis focused on MAVS, the downstream adapter molecule of RIG-I 
that is crucial for signal transduction. It is a central signaling hub in this pathway since the 
signaling of RIG-I and MDA5 culminates here and bifurcates downstream into different 
signaling branches like the IFN- or NFκB pathway or autophagy. We aimed at a better 
understanding of the regulatory mechanism by searching for novel MAVS interaction 
partners. 
Using the method of proximity-based APEX-mediated live cell tagging we were able to show 
that APEX when fused to the cytosolic part of MAVS is highly suitable to identify MAVS 
interaction partners. We identified 31 proteins in the proximity of MAVS 60 min after RLR 
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activation with triphosphate RNA (3p-RNA) that were significantly enriched in comparison to 
the unstimulated control. Within this data set we found eleven proteins that are well described 
as part of the MAVS signaling platform, such as the crucial downstream molecules TBK1, 
TRAF2, TRAF6 and the IKK kinases IKKα, β, γ (NEMO). Further six of the identified proteins 
are indirectly linked to MAVS, e.g. through interaction with described binding partners of 
MAVS, such as OPTN or TNIP1.  
UBASH3B, one of the proteins that were enriched 60 min after stimulation with 3p-RNA but 
had no known link to MAVS so far was chosen to be analyzed in more detail, because it was 
the most significantly enriched protein besides known interactors and an initial knockout 
screen indicated a MAVS-specific phenotype. 
Using two different sgRNAs and two different human cell lines (1205 Lu melanoma cells, 
immortalized human fibroblasts) with up to five single cell clones we could show that the loss 
of UBASH3B caused an enhanced immune response upon 3p-RNA stimulation measured by 
cytokine induction (e.g. IP-10, IL-6) especially at early time points after signal activation. The 
analysis of MAVS activation via its aggregate formation further showed earlier and more 
MAVS aggregation in the absence of UBASH3B, that was in line with earlier activation of 
TBK1, IRF3 and IκBα. These data indicate that UBASH3B is a negative regulator by inhibiting 
the formation of MAVS aggregates early after activation.  
All in all, the present thesis contributes to a better understanding of the antiviral RLR pathway 
by describing natural RIG-I ligands and by identification of novel MAVS interaction partners 
that in proof-of-concept studies indeed seem to play a role in the RLR pathway.  
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6 Zusammenfassung 
Das Auslösen einer angemessenen Antwort des angeborenen Immunsystems nach einer 
Virusinfektion ist entscheidend, um die Virusreplikation einzuschränken und das adaptive 
Immunsystem zu aktivieren. RIG-I-like Rezeptoren (RLRs) erkennen virale RNA-Muster im 
Zytosol und sind für die Erkennung vieler RNA-Viren von entscheidender Bedeutung. RLR-
Liganden sind als Adjuvantien für Impfstoffe und als Tumortherapie in der Entwicklung. 
Umgekehrt wurden Gain-of-function-Mutationen in RLR-Proteinen als Ursache für 
angeborene auto-inflammatorische Syndrome identifiziert. 
Obwohl die erforderlichen RNA Eigenschaften, um den Rezeptor zu aktivieren und viele 
wichtige Moleküle des RLR-Signalwegs bereits definiert sind, sind die konkreten RNA-
Spezies, die RIG-I im natürlichen Verlauf einer Infektion aktivieren, weniger charakterisiert. 
Weiterhin ist noch unvollständig verstanden, wie dieser Signalweg reguliert wird, um eine 
adäquate Immunantwort auszulösen und überschießende Reaktionen zu vermeiden. 
Ziel dieser Arbeit war es deshalb, die Liganden von RIG-I während der Infektion mit dem 
Vesikulären Stomatitis-Virus (VSV) als Modellvirus der Mononegavirales zu identifizieren, 
von dem bekannt ist, dass er hauptsächlich durch RIG-I erkannt wird. In einem früheren 
Projekt unserer Gruppe hatten wir zeigen können, dass ein definiertes Copy-back DI-Genom 
von VSV mit RIG-I assoziiert. Nach der Analyse von RIG-I-gebundener RNA mittels Deep 
Sequencing wurde die genaue Sequenz dieses DI-Genoms identifiziert und zeigte perfekte 
Eigenschaften eines RIG-I-Liganden mit einem kurzen doppelsträngigen Teil und einer 
5'-Tripiphosphat-Gruppe. 
In der hier vorgestellten Arbeit konnten wir diese Daten ergänzen und zeigen, dass sich das 
identifizierte DI-Genom während der Infektion repliziert. Durch serielle Verdünnung des 
Virusstamms wurden die DI-Genome heraus verdünnt, was den Vergleich von DI-reichen- 
mit DI-armen-Virusstämmen ermöglichte. Dies zeigte, dass DI-reiche Stocks eine viel 
stärkere Interferonantwort auslösten. Ein RNA-Fragmentierungs-Assay zeigte weiterhin, dass 
die RNA mit der höchsten immunstimulierenden Kapazität in unseren DI-reichen Stocks eine 
Größe aufweist, die der Größe des identifizierten DI-Genoms entspricht (4719 bp). Dies 
bestätigte, dass die Bindung des DI-Genoms an RIG-I den antiviralen Signalweg auslöst. In 
Abwesenheit von DI-Genomen zeigten der RNA-Fragmentierungs-Assay und die RIG-I-Co-
Immunopräzipitation, dass auch Leader/N-Sequenzen und zu einem kleineren Teil das VSV-
Volllängen-Genom die Immunantwort über RIG-I induzieren. 
Im zweiten Teil konzentrierte sich die Arbeit auf MAVS, welches das stromabwärts gelegene 
Adaptermolekül von RIG-I ist und für die Signaltransduktion eine entscheidende Bedeutung 
einnimmt. Es bildet eine zentrale Schaltstelle in diesem Signalweg, bei der die Signale von 
RIG-I und MDA5 zusammenlaufen und stromabwärts in verschiedene Richtungen, wie den 
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IFN- oder NFκB-Weg oder die Autophagie weitergegeben werden. Um die Mechanismen der 
Regulation an dieser Schaltstelle besser zu verstehen, war es das Ziel weitere MAVS-
Interaktionspartner zu identifizieren. 
Mit der Methode des APEX-vermittelten Markierens benachbarter Proteine in lebenden 
Zellen konnten wir zeigen, dass APEX, wenn es mit dem zytosolischen Teil von MAVS 
fusioniert ist, sehr gut geeignet ist, um MAVS-Interaktionspartner zu identifizieren. Wir 
konnten 60 Minuten nach der RLR-Signalaktivierung mittels Triphosphat-RNA (3p-RNA) 31 
Proteine in der Nähe von MAVS identifizieren, die im Vergleich zur unstimulierten Kontrolle 
signifikant angereichert waren. In diesem Datensatz fanden wir elf Proteine, die als Teil der 
MAVS-Signalplattform bereits gut beschrieben sind, wie die stromabwärts gelegenen 
Moleküle TBK1, TRAF2, TRAF6 und die IKK-Kinasen IKKα, β, γ (NEMO). Weitere sechs der 
identifizierten Proteine sind indirekt in der Literatur als mit MAVS verbunden beschrieben, 
d.h. durch Interaktion mit beschriebenen Bindungspartnern von MAVS, wie OPTN oder 
TNIP1. 
UBASH3B, eines der Proteine, die 60 Minuten nach der Stimulation mit 3p-RNA angereichert 
waren und bisher nicht als Interaktoren von MAVS in der Literatur beschrieben waren, wurde 
zur detaillierteren Analyse ausgewählt, da es neben den bekannten Interaktoren das Protein 
mit der signifikantesten Anreicherung war. Weiterhin wiesen erste Versuche mit Knockout-
Zellen auf einen MAVS-spezifischen Phänotyp hin. 
Unter Verwendung zweier verschiedener sgRNAs und zweier humaner Zelllinien (1205 Lu-
Melanomzellen und immortalisierte humane Fibroblasten) mit jeweils bis zu fünf 
verschiedenen Einzel-Zellklonen konnten wir zeigen, dass der Verlust von UBASH3B nach 
3p-RNA-Stimulation eine verstärkte Immunantwort hervorrief, die anhand von 
Zytokinbildung (z.B. IP-10, IL-6) gemessen wurde. Dieser Effekt war insbesondere zu frühen 
Zeitpunkten nach der Signalaktivierung nachweisbar. Die Analyse der MAVS-Aktivierung 
über ihre Aggregatbildung zeigte weiterhin eine frühere und stärkere MAVS-Aggregation bei 
Fehlen von UBASH3B, die mit der früheren Aktivierung von TBK1, IRF3 und IκBα einherging. 
Anhand dieser Daten vermuten wir, dass UBASH3B ein Negativ-Regulator des RLR-
Signalweges ist, indem er die Bildung von MAVS-Aggregaten früh nach der Signalaktivierung 
hemmt. Es sind jedoch weitere Studien erforderlich, um den genauen Mechanismus der 
Signalmodulation aufzuklären. 
Zusammengefasst trägt die vorliegende Arbeit zu einem besseren Verständnis des antiviralen 
RLR-Signalwegs bei, indem natürliche RIG-I-Liganden beschrieben und neue MAVS-
Interaktionspartner identifiziert wurden, von denen gezeigt werden konnte, dass sie 
tatsächlich im RLR-Signalweg funktionell eine Rolle spielen. 
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8 Appendices  
8.1 List of identified candidate proteins 
Table 2: List of identified candidate proteins. The proteins are listed in the order of their significance 
level beginning with the most significant. Proteins in bold back are known as part of the MAVS signaling 
complex. Proteins highlighted in bold grey have an indirect connection to MAVS.  
P-value 
(-Logp) 
Difference  
(LFQ intensity) Gene name 
9,005013374 -4,380057653 TBK1 
8,240475337 -7,393762906 RNF31 
8,207464697 -6,012409846 TRAF2 
7,816895025 -4,99873956 IKBKG (NEMO) 
7,30927026 -3,044510841 BIRC2 
6,539345024 -2,495058378 UBASH3B 
6,18272406 -3,121424357 OPTN 
5,940226096 -3,910493533 SHARPIN 
5,647112211 -3,873440742 IKBKB (IKKβ) 
5,614276172 -3,129470825 CHUK (IKKα) 
5,038177645 -1,653711637 OPA1 
4,984357487 -2,000564575 RBCK1 
4,721023467 -0,629809697 ATAD3A 
4,481846556 -2,546969414 TAX1BP1 
4,414132706 -2,48865668 N4BP1 
4,37275035 -1,147908211 SRI 
4,28042528 -3,163050334 CHCHD3 
4,12899366 -0,97087129 IMMT 
3,902281941 -2,139049848 TNIP1 
3,494645291 -1,627751668 WIPI1 
3,284339545 -1,493394534 CCDC50 
3,247751353 -0,796626409 CYB5R3 
3,149360636 -2,290521304 TNC 
3,147355109 -0,972751935 DNM1L (DRP1) 
3,062151132 -0,940523465 TBC1D15 
2,734228071 -2,407656352 TRAF6 
2,605307632 -0,92519029 ANXA7 
2,599994702 -0,970018705 TAGLN2 
2,566233406 -1,489706675 TANK 
2,491821171 -1,36869367 ARMC10 
2,449905255 -1,127365112 LGALS3 
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8.2 List of quantitative reverse transcriptase PCR primers and probes 
Table 3: List of qRT-PCR primer and probes. The primers were designed using the online assay design center of 
Roche Universal probe library (UPL) and obtained from Metabion. The assays without a UPL probe were designed 
manually and the probes were obtained from Molbiol. 
Target 
gene Forward primer (5´→ 3´) Reverse primer (5´→ 3´) probe  
human    
HPRT tgaccttgatttattttgcatacc cgagcaagacgttcagtcct UPL #73 
IFN-β cgacactgttcgtgttgtca gaggcacaacaggagagcaa  UPL #25 
IL-1β ctgtcctgcgtgttgaaaga ttgggtaatttttgggatctaca UPL #78  
IL-6 gatgagtacaaaagtcctgatcca ctgcagccactggttctgt UPL #40 
IP-10 gaaagcagttagcaaggaaaggt gacatatactccatgtagggaagtga UPL #34 
UBASH3B gctggacgtgctcctctc agtcacatgctgcctgaaca UPL #69 
murine    
β-actin ggagcagaaggagattactgc ccaccgatccacacagagta UPL #63 
GAPDH agcttgtcatcaacgggaag tttgatgttagtggggtctcg UPL #9 
IFN-β tccagaatgtctttcttgtcttca gacgtacaacaatagtctcattcca UPL #67 
IL-1β tgagcaccttcttttccttca catctcggagcctgtagtgc UPL #62 
IL-6 tgatggatgctaccaaactgg ttcatgtactccaggtagctatgg UPL #6 
IP-10 atcagcaccatgaacccaag cctatggccctcattctcac  UPL #3 
VSV    
Leader/N cgaagacaaacaaaccattattatca gttgtcaatgattctcttgactgtaac UPL #2 
N cgaagacaaacaaaccattattatca tctgcaacttctcggttcaa UPL #85 
P gcagagtgcacatttgaagc  agttatctggcgctccttcat  UPL #7 
M gcgaaggcagggcttatt gctctggtacattgagcatgg UPL #60 
G tggttcgagatggctgataa acttgacccttctgggcatt UPL #71 
L cctttagaagggaattggaagaa tctgccgacttgataggattg UPL #62 
L/trailer catgaggagactccaaac  gacgaagaccacaaaacc  tcttgtggtttttattttttatc
tgg 
Trailer ggctttgatccttaagacc gacgaagaccacaaaacc tcttgtggtttttattttttatc
tgg 
DI genome cgcgggacgaagaccacaaaa gccgtttgataacttcctttggtg tcttgtggtttttattttttatc
tgg  
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8.3 List of sgRNAs and its oligonucleotides  
Table 4: List of sgRNAs and its oligonucleotides. The sgRNAs were designed with the online tool 
http://chopchop.cbu.uib.no and the corresponding oligonucleotides flanked by the BbsI restriction sites (in italic) 
were ordered by Metabion.  
Target 
gene sgRNA Oligo top strand (5´→ 3´) 
Oligo bottom strand (5´→ 
3´) 
CCDC50          gtaactatctgcataagcacg
gg 
caccgtaactatctgcataagcac aaacgtgcttatgcagatagttac 
CHCHD3 
 
gatgttgcttttccagctttcg
g 
caccgatgttgcttttccagcttt aaacaaagctggaaaagcaacatc 
N4BP1 gaccttgcatcagtaaccgaa
gg 
caccgaccttgcatcagtaaccga  aaactcggttactgatgcaaggtc 
OPTN gatttgaggagctttcggcct
gg 
caccgatttgaggagctttcggcc aaacggccgaaagctcctcaaatc 
SRI gcagcaaagtaaccatacag
cgg 
caccgcagcaaagtaaccatacag aaacctgtatggttactttgctgc 
TNC gttgccccgaccgctacaga
agg 
caccgttgccccgaccgctacaga aaactctgtagcggtcggggcaac 
UBASH3B 
sg1 
gacgacgtatagagctccag
ggg 
caccgacgacgtatagagctccag aaacctggagctctatacgtcgtc 
UBASH3B 
sg2 
ggctggctgttgaccctcagc
gg 
caccggctggctgttgaccctcag aaacctgagggtcaacagccagcc 
WIPI1 gcctgaggcattgaaggtga
tgg 
caccgcctgaggcattgaaggtga aaactcaccttcaatgcctcaggc 
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8.4 List of primers for target site amplification 
Table 5: List of primers for target site amplification. The listed primers were obtained from Metabion and 
expected amplicon size is given with the expected fragment after T7 digestion. 
Target 
gene Forward primer (5´→ 3´) Reverse primer (5´→ 3´) 
Amplicon (T7 
cleaved) (bp) 
CCDC50          tgttaagcagtcatctggcatt tgccacacatctaaatgtaccc 425 (170/255) 
CHCHD3 taaaggagtagtgctgtggggt ggattcaagagtgggaagagaa 520 (330/190) 
N4BP1 acagaaacatgaagtctggggt tacgtaattgcaacattgctcc 480 (170/310) 
OPTN tcctggtatctcaagatggctt cagatgacctttctgatttccc 650 (150/400) 
SRI tggcttacctagtttgcactca aagcaaagggactcagtaccac 500 (250/250) 
TNC acaaatggttctcaagccagat tgttgagacacagaggcttgtt 540 (160/380) 
UBASH3B 
sg1 atgccaatgttaagtagcagca ctgaattaggaggagatggtgg 420 (180/240) 
UBASH3 
sg2 ttaatggccaaatgctactcct 
ccagtacttcccaaacacaaca 
365 (95/270) 
WIPI1 gagggagaaaggagaaaagagg attccaggcagaagacatcaat 550 (400/150) 
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8.5 List of abbreviations 
3p-RNA Triphosphate RNA 
Aa Amino acid 
ALR AIM2-like-receptors 
APEX Ascorbate peroxidase 
ATP Adenosine triphosphate 
BHK Baby hamster kidney 
BMDM Bone marrow-derived macrophage 
BME β-Mercaptoethanol 
Bp Base pair 
BSA Bovine serum albumine 
CARD Caspase recruitment domain 
cDNA Complementary DNA 
CHX Cycloheximide 
CLR C-type-lectine receptor 
CTD Carboxy-terminal domain 
DI Defective interfering 
DNA Desoyribonucleic acid 
Dox Doxycycline 
Ds Double stranded 
ECL 
e.g. 
Enhanced chemiluminescence 
Exempli gratia 
EGFR Epidermal growth factor receptor 
ELISA Enzyme-linked immunosorbent assay 
EMCV Encephalomyocarditis virus 
ER Endoplasmic reticulum 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
FL Full-length 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
GPCR G-protein-coupled receptor 
h Hour 
H2O2 Hydrogen peroxide 
HEK Human embryonic kidney 
Hpi Hours post infection 
HRP Horse radish peroxidase 
hTERT Human telomerase reverse transcriptase 
i.e. Id est 
IFN Interferon 
IKKα IκB kinase α 
IL-6 Interleukin 6 
IMM Inner mitochondrial membrane 
IMS Mitochondrial intermembrane space 
IP Immunoprecipitation 
IP-10 Interferon γ induced protein 10 
IRF3 Interferon regulatory factor 3 
ISG Interferon-stimulated gene 
Kb Kilo base pair 
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KDa Kilo Dalton 
KEGG Kyoto encyclopedia of genes and genomes 
KO Knockout 
LC/MS Liquid chromatography/ mass spectrometry 
LFQ Label-free quantification 
LGP2 Laboratory of genetics and physiology 2 
M Molar 
MAM Mitochondria-associated membranes 
MAVS Mitochondrial antiviral signaling protein 
M-CSF Macrophage colony-stimulating factor 
MDA5 Melanoma differentiation antigen 5 
Min Minute 
MOI Multiplicity of infection 
mRNA Messenger RNA 
MS Mass spectrometry 
MV Measles virus 
NEMO NFκB essential modulator 
NES Nuclear export sequence 
NFκB Nuclear factor κ B 
NGS Next generation sequencing 
NLR NOD-like receptors 
nt Nucleotide 
OMM Outer mitochondrial membrane 
OPTN Optineurin 
P- Phospho- 
PAMP Pathogen-associated molecular pattern 
PBS Phosphate-buffered saline 
PCA Principal component analysis 
PCR Polymerase chain reaction 
pIC Polyinosinic:polycytidylic acid 
PPI Protein protein interaction 
PRR Pattern recognition receptor 
PVDF Polyvinyliden fluoride 
qRT-PCR Quantitative reverse transcriptase PCR 
RIG-I Retinoic acid inducible gene I 
RLR RIG-I-like receptor 
RNA Ribonucleic acid 
RNP Ribonucleoprotein  
ROS Reactive oxygen species 
RT Room temperature 
SCC Single cell clone 
SDS Sodium dodecyl sulfate 
SDS-PAGE SDS polyacrylamide gel electrophoresis 
Sec Second 
SEM Standard error of mean 
sgRNA Single-guide RNA 
SRI Sorcin 
Ss Single-stranded 
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STING Stimulator of interferon genes  
TANK TRAF family member associated NFκB activator 
TBK1 TANK binding kinase 1 
TBS Tris-buffered saline 
TCR T-cell receptor 
Tet Tetracycline 
TIM TRAF-interacting motifs 
TLR Toll-like receptors 
TM Transmembrane 
TNBC Triple-negative breast cancer 
TNC Tenascin C 
TRAF TNF receptor-associated factor 
Ut Untransfected 
UTR Untranslated region 
VSV Vesicular stomatitis virus 
Wt Wildtype 
Y2H Yeast-two-hybrid 
Δψm Mitochondrial membrane potential 
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